


SYNTHESIS, ANTIFUNGAL AND ANTI-HIV ACTIVITIES OF NEW
HETEROCYCLIC COMPOUNDS

HELMI MOHAMMED ABDULGHANI AL-MAQTARI

A thesis submitted in fulfilment of the
requirements for the award of the degree of
Doctor of Philosophy (Chemistry)

Faculty of Science
Universiti Teknologi Malaysia

FEBRUARY 2019



Dedicated to

My beloved parents

My beloved wife

My son, Bakil and My daughter, Azal

My beloved grandmother

ACKNOWLEDGEMENT

At the first, my deepest thankfulness and gratefulness to Allah for helping, giving me the strength, the sound health, patience to complete this work.

I do express my whole hearted thanks to Dr. Joazaizulfazli Jamalis for his support, suggestions, insights, guidance, patience during my PhD Journey and supervision of this study. I am also thankful to my co-supervisor: Dr. Siti Pauliena Mohd Bohari for their guidance, encouragement and excellent advice throughout this work.

My cordial thanks to all the faculty members of chemistry department, Faculty of Science, UTM especially to my past co-supervisor, prof. Dr. Hasnah Mohd Sirat and Prof. Dr. Farediah Ahmad for their encouragement and guidance. My thanks should be also dedicated to all lab assistants: Madam Zahratul Ain Jalil, Mr. Azmi, Mr. Rasyidi, Mr. Subre, Mr. Amin and Mrs.Nurnazmin for providing me instrumental facilities, kind cooperation throughout the study. I wish to thanks to my fellow colleagues: Dr. Salam, Dr. Aminu, Dr. Saidu, Dr. Abdo Al-fakih, Dr. Kamal, Dr. Murad Saeed, Dr. Nuzul, Zakiah, Aisyah, Athirah and Shafiq. I extend thanks also to my PhD scholarship by Hodeidah University, Republic of Yemen for the support during my study.

Last but not least, I am most grateful to lovely family including my parents, my wife, my son, my daughter and grandmother for their great support, encouragement, kindness understanding, endless patience and sincere prayers to me during my PhD journey. Thank you.

ABSTRACT

Thiophene chalcones, pyrazolines and 1,5-benzodiazepines are important heterocyclic compounds which show broad spectrum of biological activities. Three series of heterocyclic chalcones and their *N*-acetylated pyrazoline derivatives have been synthesized in low to good yields. The first step in this study is the synthesis of 3-acetyl-2,5-dichlorothiophene and 2-acetyl-5-chlorothiophene as heterocyclic ketones using Friedel-Crafts acylation. All thiophene chalcones were synthesized in three separate reactions by Claisen-Schmidt reaction of substituted thiophene aldehydes with ketones. Several acetophenone derivatives (series 2 and 3) were produced by cyclization reaction using hydrazine hydrate to form new and known *N*-acetylated pyrazoline derivatives. A series of substituted 1,5-benzodiazepines were synthesized in moderate to good yields. 4-Methyl-1,3,4,5-tetrahydro-2*H*-1,5-benzodiazepin-2-one was synthesized as starting material by reacting *ortho* phenylenediamine and crotonic acid in the presence of toluene. Cyclization of the starting material with appropriate acid chlorides, unsubstituted and five types of groups (fluoro, chloro, bromo, methyl and methoxy) attached at *ortho*, *para* and *meta* position of phenyl ring in the presence of triethylamine and anhydrous tetrahydrofuran have furnished substituted 1,5-benzodiazepines. The structures of the compounds were confirmed by infrared (IR), ¹H NMR and ¹³C NMR (1D and 2D) nuclear magnetic resonance spectroscopies. Compounds of series 2 and 3 were tested for their antifungal activities against two types of pathogenic strains, namely *Candida albicans* and *Aspergillus niger* with fluconazole as standard drug. The results for series 2 showed that the presence of bromo and methoxy substitution at *para* position on phenyl ring in chalcone and pyrazoline, respectively, resulted in significant enhancement in potency against both tested fungal strains with MIC value of >64 µg/mL. Compound carrying *para* fluoro on phenyl ring in pyrazoline derivatives exhibited the highest potency with MIC value of >32 µg/mL and 64 µg/mL against *C. albicans* and *A.niger*, respectively, among the series 3. The anti-HIV-1 RT assay of substituted 1,5-benzodiazepines (series 4) showed that the presence of chloro substitution at *meta* and *ortho* position inhibited the activity of HIV-1 RT with IC₅₀ values 6.87 and 8.62 µM, respectively.

ABSTRAK

Tiofena kalkon, pirazolina dan 1,5-benzodiazepina adalah sebatian heterosiklik penting yang menunjukkan aktiviti biologi yang pelbagai. Tiga siri heterosiklik kalkon dan terbitan *N*-asetil pirazolina telah disintesis dengan hasil yang rendah hingga hasil yang baik. Langkah pertama dalam kajian ini ialah sintesis 3-asetil-2,5-diklorotiofena dan 2-asetil-5-klorotiofena sebagai keton heterosiklik menggunakan pengasilan Friedel-Crafts. Semua tiofena kalkon disintesis dalam tiga tindak balas berasingan dengan tindak balas Claisen-Schmidt aldehyd tiofena tertukar ganti dengan keton. Beberapa terbitan asetofenon (siri 2 dan 3) telah dihasilkan dengan tindak balas pensiklikan menggunakan hidrazina hidrat untuk menghasilkan terbitan pirazolina *N*-asetil yang baharu dan yang diketahui. Satu siri 1,5-benzodiazepina tertukar ganti telah disintesis dengan hasil yang sederhana hingga hasil yang baik. 4-Metil-1,3,4,5-tetrahidro-2*H*-1,5-benzodiazepin-2-on telah dihasilkan sebagai bahan pemula melalui tindak balas *orto* fenilenadamina dan asid krotonik dengan kehadiran toluena. Pensiklikan bahan pemula itu dengan asid klorida yang sesuai, fenil tanpa penukarganti dan gelang fenil dengan lima jenis kumpulan (fluoro, kloro, bromo, metil dan metoksi) yang terikat pada kedudukan *orto*, *para* dan *meta* dengan kehadiran trietilamina dan tetrahidrofuran kontang telah menghasilkan 1,5-benzodiazepina tertukar ganti. Struktur sebatian disahkan dengan spektroskopi inframerah (IR) dan resonans magnet nucleus ^1H NMR dan ^{13}C NMR (1D dan 2D). Sebatian siri 2 dan 3 telah diuji untuk aktiviti antikulat terhadap dua jenis patogen, iaitu *Candida albicans* dan *Aspergillus niger* dengan flukonazol digunakan sebagai dadah piawai. Keputusan bagi siri 2 menunjukkan bahawa kehadiran bromin dan metoksi masing-masing pada kedudukan *para* pada gelang fenil dalam kalkon dan pirazolina, menghasilkan peningkatan ketara dalam potensi terhadap kedua-dua strain kulat yang diuji dengan nilai MIC > 64 $\mu\text{g}/\text{mL}$. Sebatian yang mengandungi fluoro *para* pada gelang fenil dalam terbitan pirazolina mempamerkan potensi tertinggi dengan nilai MIC 32 $\mu\text{g}/\text{mL}$ dan 64 $\mu\text{g}/\text{mL}$ masing-masing terhadap *C. albicans* dan *A.niger* dalam siri 3. Pengujian anti-HIV-1 RT terhadap 1,5-benzodiazepin tertukar ganti (siri 4) menunjukkan bahawa kehadiran kloro pada kedudukan *meta* dan *orto* merencatkan aktiviti HIV-1 RT masing-masing dengan nilai IC_{50} 6.87 dan 8.62 μM .

TABLE OF CONTENTS

| CHAPTER | TITLE | PAGE |
|----------------|-----------------------------------|-------------|
| | DECLARATION | ii |
| | DEDICATION | iii |
| | ACKNOWLEDGEMENT | iv |
| | ABSTRACT | v |
| | ABSTRAK | vi |
| | TABLE OF CONTENTS | vii |
| | LIST OF TABLES | xx |
| | LIST OF FIGURES | xxii |
| | LIST OF SCHEMES | xxiii |
| | LIST OF ABBREVIATIONS | xxvii |
| | LIST OF APPENDICES | xxxii |
| 1 | INTRODUCTION | 1 |
| | 1.1 Background of Study | 1 |
| | 1.2 Problem Statement | 3 |
| | 1.3 Objectives of Study | 4 |
| | 1.4 Scopes of Study | 5 |
| | 1.5 Significance of Study | 6 |
| 2 | LITERATURE REVIEW | 7 |
| | 2.1 Chemistry of Chalcone | 7 |
| | 2.2 Naturally Occurring Chalcones | 8 |
| | 2.3 Methods of Chalcone Synthesis | 16 |

| | | |
|-------|------------------------------------------------------------------|----|
| 2.3.1 | Friedel-Crafts Acylation | 17 |
| 2.3.2 | Suzuki Coupling Reaction | 18 |
| 2.3.3 | Synthesis of Chalcones via Claisen-Schmidt Reaction | 19 |
| 2.3.4 | Synthesis of Chalcones Using Microwave Irradiation (MWI) | 21 |
| 2.3.5 | Synthesis of Chalcones under Ultrasound Irradiation (U.S) | 23 |
| 2.3.6 | Synthesis of Chalcones via Grinding Technique | 25 |
| 2.3.7 | Synthesis of Chalcones by Using Boron Trifluoride Ethyl Etherate | 27 |
| 2.4 | Biological Activity of Chalcone | 29 |
| 2.4.1 | Antifungal Activity | 29 |
| 2.4.2 | Other Biological Activities of Thiophene Chalcone | 33 |
| 2.5 | Chemistry of Pyrazoline | 39 |
| 2.6 | Synthesis of Pyrazoline Derivatives | 40 |
| 2.6.1 | Synthesis of Pyrazoline Derivatives from Diazomethane | 40 |
| 2.6.2 | Ultrasound Method (US) | 41 |
| 2.6.3 | Grinding Method | 43 |
| 2.6.4 | Microwave Method | 43 |
| 2.6.5 | Conventional Methods | 46 |
| 2.7 | Biological Activity of Pyrazoline Derivatives | 49 |
| 2.7.1 | Antifungal Activity | 49 |
| 2.7.2 | Other Biological Activities of Pyrazoline Derivatives | 56 |
| 2.8 | Chemistry of Benzodiazepines | 60 |
| 2.9 | Naturally Occurring Benzodiazepine Derivatives | 62 |
| 2.9.1 | Occurrence in Human and Mammalian Tissues | 62 |

| | | |
|----------|------------------------------------------------------------------------------------------|----|
| 2.9.2 | Occurrence in Plant Products | 63 |
| 2.10 | Synthesis of 1,5-Benzodiazepines | 64 |
| 2.10.1 | Synthesis of 1,5-Benzodiazepine Derivatives by Using Nontraditional Methods | 66 |
| 2.10.1.1 | Synthesis of 1,5-Benzodiaze- pine Derivatives under Ultrasound Irradiation (U.S) | 66 |
| 2.10.1.2 | Synthesis of 1,5-Benzodiaze- pine Derivatives Using Microwave Irradiation (MWI) | 67 |
| 2.10.2 | Synthesis of 1,5-Benzodiazepine- Derivatives by Using Traditional Methods | 68 |
| 2.10.2.1 | Synthesis of 1,5-Benzodiaze pine Derivatives from Ketones | 68 |
| 2.10.2.2 | Synthesis of 1,5-Benzodia- zepine Derivatives from β - Ketoester | 70 |
| 2.10.2.3 | Synthesis of 1, 5-Benzodia- zepine Derivatives from β - Aminoketons | 71 |
| 2.10.2.4 | Synthesis of 1,5-Benzodia- zepin-2-one Derivatives by Using Philip's Reaction | 71 |
| 2.11 | Biological Activity of Benzodiazepine Derivatives | 74 |
| 2.11.1 | Anti-HIV Activity | 76 |
| 2.11.1.1 | Introduction to HIV | 76 |
| 2.11.1.2 | Antiretrovirals (ARVs) Therapy | 77 |

| | | |
|----------|------------------------------------------------------------------------------------------------------------------------------------|-----------|
| | 2.11.1.3 Anti-HIV-1 RT Activity of 1,5-Benzodiazepine Derivatives | 80 |
| | 2.11.2 Other Biological Activities of Benzodiazepine Derivatives | 87 |
| 3 | RESULTS AND DISCUSSION | 91 |
| 3.1 | Synthesis of 3-Acetyl-2,5-dichlorothiophene (246) and 2-Acetyl-5-chlorothiophene (247) | 91 |
| 3.2 | Synthesis of Heterocyclic Chalcones (250- 255) | 92 |
| 3.3 | Chemistry of Heterocyclic Chalcones (264- 271) and (272-278) | 98 |
| | 3.3.1 Synthesis of Heterocyclic Chalcones (264-271) | 99 |
| | 3.3.1.1 Synthesis (<i>E</i>)-3-(5-Bromothio- phen-2-yl)-1-(4-chloro phen yl)prop-2-en-1-one (265) | 102 |
| | 3.3.2 Synthesis of Heterocyclic Chalcones (272-278) | 106 |
| | 3.3.2.1 (<i>E</i>)-1-(4-Iodophenyl)-3-(3- methylthiophen-2-yl) prop-2- en-1-one (276) | 109 |
| 3.4 | Synthesis of Pyrazoline Derivatives (279- 284) | 113 |
| | 3.4.1 1-(3-(5-Chlorothiophen-2-yl)-5-(3- methyl thiophen-2-yl)-4,5-dihydro-1 <i>H</i> - pyrazol-1-yl)ethanone (283) | 114 |
| 3.5 | Chemistry of Pyrazolines Derivatives (285- 292) | 118 |
| | 3.5.1 Plausible Reaction Mechanism of <i>N</i> - acetyl Pyrazoline Derivatives | 119 |
| | 3.5.2 Synthesis of Pyrazolines Derivatives | 121 |

| | | |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| | (285-292) | |
| 3.5.2.1 | 1-(5-(5-Bromothiophen-2-yl)-3-(4-nitro phenyl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (292) | 122 |
| 3.5.3 | Synthesis of Pyrazoline Derivatives (293-299) | 126 |
| 3.5.3.1 | Synthesis of 1-(5-(3-Methylthiophen-2-yl)-3- <i>p</i> -tolyl-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (298) | 128 |
| 3.6 | Synthesis of 4-Methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (199) and Synthesis of Substituted 1,5-Benzodiazepines (316-331) | 132 |
| 3.6.1 | Synthesis of 4-Methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (199) | 135 |
| 3.6.2 | Synthesis of Substituted 1,5-Benzodiazepines (316-331) | 135 |
| 3.6.2.1 | 5-(4-Methoxybenzoyl)-4-methyl-1,3,4,5-tetrahydro -2 <i>H</i> -1,5-benzodiazepin-2-one (328) | 137 |
| 3.7 | Biological Activities | 142 |
| 3.7.1 | Antifungal Activity of Thiophene Chalcones (264-271) | 142 |
| 3.7.2 | Antifungal Activity of Pyrazoline Derivatives (285-292) | 143 |
| 3.7.3 | Antifungal Activity of Thiophene Chalcones (272-278) | 145 |
| 3.7.4 | Antifungal Activity of Pyrazoline Derivatives (293-299) | 147 |
| 3.7.5 | Anti-HIV-1 RT Activity of 1,5-Benzo | 150 |

| | | |
|----------|------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| | diazepine Derivatives (316-323, 325, 327-331) | |
| | 5.7.5.1 Cytotoxicity Assay | 152 |
| 4 | EXPERIMENTAL | 154 |
| | 4.1 Chemicals and Reagents | 154 |
| | 4.2 Instrumentation | 155 |
| | 4.3 Synthesis of Heterocyclic Compounds | 156 |
| | 4.3.1 General Procedure for the Synthesis of 3-Acetyl-2,5-dichlorothiophene (246) and 2-Acetyl-5-chlorothiophene (247) | 156 |
| | 4.3.2 General Procedure for Synthesis of Thiophene Chalcones (250-255) | 157 |
| | 4.3.2.1 Synthesis of 1-(2,5-Dichloro thiophen-3-yl)-3-(thiophen-2- yl)-2-propen-1-one (250) | 157 |
| | 4.3.2.2 Synthesis of 1-(2,5-Dichloro thiophen-3-yl)-3-(3-methyl- thiophen-2-yl)-2-propen-1- one (251) | 158 |
| | 4.3.2.3 Synthesis of 3-(5-Bromothio phen-2-yl)-1-(2,5-dichloro thiophen-3-yl)-2-propen-1- one (252) | 158 |
| | 4.3.2.4 Synthesis of 1-(5-Chloro thio phen-2-yl)-3-(thiophen-2-yl)- 2-propen-1-one (253) | 159 |
| | 4.3.2.5 Synthesis of 1-(5-Chloro thio phen-2-yl) -3-(3-methyl-thio phen-2-yl)-2-propen-1-one (254) | 159 |
| | 4.3.2.6 Synthesis of 3-(5-Bromo-thio phene-2-yl)-1-(5-chloro thio | 159 |

| | | |
|----------|---------------------------------------------------------------------------------------------------|-----|
| | phen-2-yl)-2-propen-1-one (255) | |
| 4.3.3 | General Procedure for Synthesis of Chalcones (264-271) | 160 |
| 4.3.3. 1 | (<i>E</i>)-3-(5-Bromothiophen-2-yl) -1-phenylprop-2-en-1-one (264) | 160 |
| 4.3.3. 2 | (<i>E</i>)-3-(5-Bromothiophen-2- yl)-1-(4-chlorophenyl)prop-2- en-1-one (265) | 161 |
| 4.3.3.3 | (<i>E</i>)-3-(5-Bromothiophen-2- yl)-1-(4-fluorophenyl)prop-2- en-1-one (266) | 161 |
| 4.3.3.4 | (<i>E</i>)-1-(4-Bromophenyl)-3-(5- bromothiophen-2-yl)prop-2- en-1-one (267) | 161 |
| 4.3.3.5 | (<i>E</i>)-3-(5-Bromothiophen-2- yl)-1-(4-iodophenyl)prop-2- en-1-one (268) | 162 |
| 4.3.3. 6 | (<i>E</i>)-3-(5-Bromothiophen-2-yl) -1-(4-methoxy phenyl) prop- 2-en-1-one (269) | 162 |
| 4.3.3. 7 | (<i>E</i>)-3-(5-Bromothiophen-2-yl) -1- <i>p</i> -tolylprop-2-en-1-one (270) | 163 |
| 4.3.3.8 | (<i>E</i>)-3-(5-Bromothiophen-2-yl) -1-(4-nitrophenyl)prop-2-en- 1-one (271) | 163 |
| 4.3.4 | General Procedure for Synthesis of Chalcones (272-278) | 163 |
| 4.3.4. 1 | (<i>E</i>)-3-(3-Methylthiophen-2-yl) -1-phenylprop-2-en-1-one (272) | 164 |

| | | |
|---------|-------------------------------------------------------------------------------------------------------------------------|-----|
| 4.3.4.2 | (<i>E</i>)-1-(4-Chlorophenyl)-3-(3-methylthiophen-2-yl)prop-2-en-1-one (273) | 164 |
| 4.3.4.3 | (<i>E</i>)-1-(4-Fluorophenyl)-3-(3-methylthiophen-2-yl)prop-2-en-1-one (274) | 165 |
| 4.3.4.4 | (<i>E</i>)-1-(4-Bromophenyl)-3-(3-methylthiophen-2-yl)prop-2-en-1-one (275) | 165 |
| 4.3.4.5 | (<i>E</i>)-1-(4-Iodophenyl)-3-(3-methylthiophen-2-yl)prop-2-en-1-one (276) | 165 |
| 4.3.4.6 | (<i>E</i>)-3-(3-Methylthiophen-2-yl)-1- <i>p</i> -tolylprop-2-en-1-one (277) | 166 |
| 4.3.4.7 | (<i>E</i>)-3-(3-Methylthiophen-2-yl)-1-(4-nitrophenyl)prop-2-en-1-one (278) | 166 |
| 4.3.5 | General Procedure for Synthesis of Pyrazolines derivatives (279-284) | 167 |
| 4.3.5.1 | 1-(3-(2,5-Dichlorothiophen-3-yl)-5-(thiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (279) | 167 |
| 4.3.5.2 | 1-(3-(2,5-Dichlorothiophen-3-yl)-5-(3-methylthiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (280) | 167 |
| 4.3.5.3 | 1-(5-(5-Bromothiophen-2-yl)-3-(2,5-dichlorothiophen-3-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (281) | 168 |

| | | |
|---------|-------------------------------------------------------------------------------------------------------------------|-----|
| 4.3.5.4 | 1-(3-(5-Chlorothiophen-2-yl)-5-(thiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl) ethanone (282) | 168 |
| 4.3.5.5 | 1-(3-(5-Chlorothiophen-2-yl)-5-(3-methylthiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (283) | 169 |
| 4.3.5.6 | 1-(5-(5-Bromothiophen-2-yl)-3-(5-chlorothiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl) ethanone (284) | 169 |
| 4.3.6 | General procedure for Synthesis of Pyrazolines Derivatives (285-292) | 170 |
| 4.3.6.1 | 1-(5-(5-Bromothiophen-2-yl)-3-phenyl-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (285) | 170 |
| 4.3.6.2 | 1-(5-(5-Bromothiophen-2-yl)-3-(4-chlorophenyl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl) ethanone (286) | 170 |
| 4.3.6.3 | 1-(5-(5-Bromothiophen-2-yl)-3-(4-fluorophenyl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl) ethanone (287) | 171 |
| 4.3.6.4 | 1-(3-(4-Bromophenyl)-5-(5-bromothiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl) ethanone (288) | 171 |
| 4.3.6.5 | 1-(5-(5-Bromothiophen-2-yl)-3-(4-iodophenyl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (289) | 172 |

| | | |
|---------|--------------------------------------------------------------------------------------------------------------|-----|
| 4.3.6.6 | 1-(5-(5-Bromothiophen-2-yl)-3-(4-methoxyphenyl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (290) | 172 |
| 4.3.6.7 | 1-(5-(5-Bromothiophen-2-yl)-3- <i>p</i> -tolyl-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (291) | 173 |
| 4.3.6.8 | 1-(5-(5-Bromothiophen-2-yl)-3-(4-nitrophenyl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (292) | 173 |
| 4.3.7 | General Procedure for Synthesis of Pyrazolines Derivatives (293-299) | 174 |
| 4.3.7.1 | 1-(5-(3-Methylthiophen-2-yl)-3-phenyl-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (293) | 174 |
| 4.3.7.2 | 1-(3-(4-Chlorophenyl)-5-(3-methylthiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (294) | 174 |
| 4.3.7.3 | 1-(3-(4-Fluorophenyl)-5-(3-methylthiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (295) | 175 |
| 4.3.7.4 | 1-(3-(4-Bromophenyl)-5-(3-methylthiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (296) | 175 |
| 4.3.7.5 | 1-(3-(4-Iodophenyl)-5-(3-methylthiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (297) | 176 |
| 4.3.7.6 | 1-(5-(3-Methylthiophen-2-yl)- | 176 |

| | |
|----------------------------------------------------------------------------------------------------------------------------------|-----|
| 3- <i>p</i> -tolyl-4,5-dihydro-1 <i>H</i> - pyrazol-1-yl)ethanone (298) | |
| 4.3.7.7 1-(5-(3-Methylthiophen-2-yl)- 3-(4-nitrophenyl)-4,5-di- hydro-1 <i>H</i> -pyrazol-1-yl) ethanone (299) | 177 |
| 4.3.8 Procedure for the Synthesis of 4- Methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5- benzodiazepin-2-one (199) | 177 |
| 4.3.8.1 4-Methyl-1,3,4,5-tetrahydro- 2 <i>H</i> -1,5-benzodiazepin-2-one (199) | 178 |
| 4.3.9 General Procedure for Synthesis of Substituted 1,5-Benzodiazepines (316- 331) | 178 |
| 4.3.9.1 5-(Benzoyl)-4-methyl-1,3,4,5- tetrahydro-2 <i>H</i> -1,5-benzo dia- zepin-2-one (316) | 178 |
| 4.3.9.2 5-(2-Chlorobenzoyl)-4-methyl -1,3,4,5-tetrahydro-2 <i>H</i> -1,5- benzodiazepin-2-one (317) | 179 |
| 4.3.9.3 5-(3-Chlorobenzoyl)-4-methyl -1,3,4,5-tetrahydro-2 <i>H</i> -1,5- benzodiazepin-2-one (318) | 179 |
| 4.3.9.4 5-(4-Chlorobenzoyl)-4-methyl -1,3,4,5-tetrahydro-2 <i>H</i> -1,5- benzodiazepin-2-one (319) | 180 |
| 4.3.9.5 5-(2-Fluorobenzoyl)-4-methyl -1,3,4,5-tetrahydro-2 <i>H</i> -1,5- benzodiazepin-2-one (320) | 180 |
| 4.3.9.6 5-(3-Fluorobenzoyl)-4-methyl -1,3,4,5-tetrahydro-2 <i>H</i> -1,5- benzodiazepin-2-one (321) | 180 |

| | | |
|----------|-----------------------------------------------------------------------------------------------------------------|-----|
| 4.3.9.7 | 5-(4-Fluorobenzoyl)-4-methyl -1,3,4,5-tetrahydro-2 <i>H</i> -1,5- benzodiazepin-2-one (322) | 181 |
| 4.3.9.8 | 5-(2-Bromobenzoyl)-4-methyl -1,3,4,5-tetrahydro-2 <i>H</i> -1,5- benzodiazepin-2-one (323) | 181 |
| 4.3.9.9 | 5-(3-Bromobenzoyl)-4-methyl -1,3,4,5-tetrahydro-2 <i>H</i> -1,5- benzodiazepin-2-one (324) | 182 |
| 4.3.9.10 | 5-(4-Bromobenzoyl)-4-meth yl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5- benzodiazepin-2-one (325) | 182 |
| 4.3.9.11 | 5-(2-Methoxybenzoyl)-4- methyl-1,3,4,5-tetrahydro-2 <i>H</i> - -1,5- benzodiazepin-2-one (326) | 182 |
| 4.3.9.12 | 5-(3-Methoxybenzoyl)-4- methyl-1,3,4,5-tetra hydro- 2 <i>H</i> -1,5-benzo diazepin-2- one (327) | 183 |
| 4.3.9.13 | 5-(4-Methoxybenzoyl)-4- methyl-1,3,4,5-tetra hydro- 2 <i>H</i> -1,5-benzo diazepin-2-one (328) | 183 |
| 4.3.9.14 | 5-(2-Methylbenzoyl)- 4-meth yl-1,3,4,5-tetra hydro-2 <i>H</i> -1,5 -benzo diazepin-2-one (329) | 184 |
| 4.3.9.15 | 5-(3-Methylbenzoyl)-4-meth yl-1,3,4,5-tetra hydro-2 <i>H</i> - 1,5-benzo diazepin-2-one (330) | 184 |
| 4.3.9.16 | 5-(4-Methylbenzoyl)-4-meth yl-1,3,4,5-tetra hydro-2 <i>H</i> - | 185 |

| | | |
|----------|----------------------------------------------------------------------------------------------------------------|------------|
| | 1,5-benzo diazepin-2-one (331) | |
| 4.4 | Bioactivity Studies | 185 |
| 4.4.1 | Antifungal Activity of Thiophene Chalcones (264-278) and Pyrazolines Derivatives (285-299) | 185 |
| 4.4.1.2 | Antifungal Screening | 186 |
| 4.4.2 | Cytotoxicity and Anti-HIV-1 RT Activity of 1,5-Benzodiazepine Derivatives (316-323, 325, 327-331) | 187 |
| 4.4.2.1 | HIV-1 RT in-vitro assay for (316-323, 325, 327-331) | 187 |
| 4.4.2.2 | Cytotoxicity Assay | 188 |
| 5 | CONCLUSION AND RECOMMENDATIONS | 190 |
| 5.1 | Synthesis of Heterocyclic Compounds | 190 |
| 5.2 | Bioactivity Studies | 191 |
| 5.3 | Recommendations | 192 |
| | REFERENCES | 193 |
| | Appendices | 236 |
| | Publications and Conferences | 360 |

LIST OF TABLES

| TABLE NO. | TITLE | PAGE |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| 3.1 | ^1H , ^{13}C and HMQC NMR data of compound (254) | 98 |
| 3.2 | ^{13}C NMR spectral data of compounds (264-266, 269-271) and the data from literature | 101 |
| 3.3 | NMR spectral data of chalcone (265) | 105 |
| 3.4 | ^{13}C NMR spectral data of compounds (272-274, 277-278) and the data from literature (Musumarra and Ballistreri, 1980) | 107 |
| 3.5 | NMR spectral data of chalcone (276) | 112 |
| 3.6 | NMR spectral data of compound (283) | 117 |
| 3.7 | ^1H , ^{13}C , COSY, HMQC and HMBC NMR data for 1-(5-(5-bromothiophen-2-yl)-3-(4-nitrophenyl)-4,5-dihydro-1H-pyrazol-1-yl)ethanone (292) | 125 |
| 3.8 | NMR spectral data of compound (298) | 131 |
| 3.9 | ^1H NMR spectral data of compound (199) and the data from literature | 132 |
| 3.10 | ^1H , ^{13}C , COSY, HMQC and HMBC NMR data for compound (328) | 141 |
| 3.11 | Antifungal activity of compounds (264-271) and standard drug | 143 |
| 3.12 | Antifungal activity of compounds (285-292) and standard drug | 145 |
| 3.13 | Antifungal activity of compounds (272-278) and standard drug | 147 |
| 3.14 | Antifungal activity of compounds (293-299) and | 150 |

| | | |
|------|------------------------------------------------------------------|-----|
| | standard drug | |
| 3.15 | Results of in-vitro HIV-1 RT inhibition and cytotoxicity studies | 153 |

LIST OF FIGURES

| FIGURE NO. | TITLE | PAGE |
|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| 2.1 | General design of heterocyclic chalcones | 8 |
| 2.2 | Structures of pyrazolines | 39 |
| 2.3 | General structure of 1 <i>H</i> -pyrazolines | 40 |
| 2.4 | Classification of benzodiazepines | 60 |
| 2.5 | Commercial drugs containing benzodiazepine derivatives | 75 |
| 2.6 | Tricyclic and tetracyclic 1,5-benzodiazepine derivatives as nevirapine analogues 227 (a-i) , 228 (a-f) , 229 (a-b) and (230-232) | 85 |
| 2.7 | 9 <i>H</i> -bis-[1,2,4]triazolo[4,3- <i>a</i> :3',4'- <i>d</i>][1,5] benzo diazepine derivatives 233 (a-n) and (234-239) | 86 |
| 3.1 | Selected HMBC correlation of compound (265) | 104 |
| 3.2 | Selected HMBC correlation of compound (276) | 111 |
| 3.3 | Selected HMBC correlation of compound (283) | 116 |
| 3.4 | Structure of pyrazoline derivatives (285-292) | 119 |
| 3.5 | Selected HMBC correlation of compound (292) | 124 |
| 3.6 | Structure of pyrazoline derivatives (293-299) | 126 |
| 3.7 | Selected HMBC correlation of compound (298) | 130 |
| 3.8 | Selected HMBC correlation of compound (328) | 140 |

LIST OF SCHEMES

| SCHEME NO. | TITLE | PAGE |
|------------|--------------------------------------------------------------------------------------------------|------|
| 2.1 | Synthesis of chalcone (45) by using Friedel-Crafts acylation | 17 |
| 2.2 | Synthesis of chalcones (48) by using Friedel-Crafts acylation with ZnO as catalyst | 18 |
| 2.3 | Synthesis of 3',4,4'-trimethoxychalcone (53) <i>via</i> Suzuki coupling reaction | 19 |
| 2.4 | Synthesis of chalcone (56) <i>via</i> Claisen-Schmidt reaction | 20 |
| 2.5 | Illustrated the synthesis of chalcone by the base-catalyzed mechanism (Claisen-Schmidt reaction) | 20 |
| 2.6 | General method for synthesis of heterocyclic chalcones <i>via</i> Claisen-Schmidt reaction | 21 |
| 2.7 | Synthesis of chalcone (69) under microwave irradiation | 22 |
| 2.8 | Synthesis of thiophene chalcone 72 (a-h) under microwave irradiation | 23 |
| 2.9 | Synthesis of chalcone (27) under ultrasound irradiation | 24 |
| 2.10 | Synthesis of thiophene chalcones (76) under ultrasound irradiation | 25 |
| 2.11 | Synthesis of chalcones 79 (a-j) under grinding technique | 26 |
| 2.12 | Synthesis of heterocyclic chalcones 82 (a-j) under | 27 |

| | | |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------|----|
| | grinding technique | |
| 2.13 | Synthesis of chalcone (85) <i>via</i> boron trifluoride ethyl etherate | 28 |
| 2.14 | Synthesis of <i>O</i> -acylated chalcone (88) and <i>N</i> -acylated chalcones (90) <i>via</i> boron trifluoride etherate | 28 |
| 2.15 | Synthesis of dimethyl 4,5-dihydro-1 <i>H</i> -pyrazole-4,5-dicarboxylate (111) | 41 |
| 2.16 | Synthesis of 1-(4-phenyl-4,5-dihydro-1 <i>H</i> -pyrazol-3-yl) ethanone (113) | 41 |
| 2.17 | Synthesis of 5-aryl-3-(thiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazole-1-carboximidamides 116 (a-l) by ultrasound technique | 42 |
| 2.18 | Synthesis of ¹ <i>N</i> -Acetyl-5-aryl-3-(substituted styryl) pyrazolines (118) by ultrasound method | 42 |
| 2.19 | Synthesis of 2-pyrazoline derivatives (120) by grinding method | 43 |
| 2.20 | Synthesis of 2-pyrazoline derivatives 121 (a-c) and (122) by microwave method | 44 |
| 2.21 | Synthesis of 2-pyrazoline derivatives (124), (125) and (126) by microwave irradiation | 45 |
| 2.22 | Synthesis of 1-phenyl-3(5-bromothiophen-2-yl)-5-(substituted phenyl)-2-pyrazolines (128) by MWI in presence of fly ash : sulfuric acid | 46 |
| 2.23 | Synthesis of <i>N</i> -acetyl-3-aryl-5-(5-(<i>ortho/para</i> -nitrophenyl)-2-furyl/thienyl)-substituted pyrazolines (131), (132) | 47 |
| 2.24 | Synthesis of the 3-(2-thienyl)-pyrazoline derivatives 133 (a-b) , 134 (a-b) , 122 b and 135 a | 47 |
| 2.25 | Synthetic route of the 5-(4-chlorophenyl)-3-(2-thienyl) pyrazoline derivatives (137), (138), (139) and (140) | 48 |
| 2.26 | Protonation of 1,5-benzodiazepine derivatives (157) | 61 |

| | | |
|------|------------------------------------------------------------------------------------------------------------------------------------|----|
| 2.27 | Synthesis of 2,4-dimethyl-3 <i>H</i> -benzo[b][1,4]diazepine (164) | 61 |
| 2.28 | Synthesis of 1,5-benzodiazepine derivatives 176 (a-l) by using (CSA) under (U.S) method | 66 |
| 2.29 | Synthesis of 2,3-dihydro 1 <i>H</i> -1,5-benzodiazepine derivatives 178 (a-i) under (U.S) method | 67 |
| 2.30 | Synthesis of 4-phenyl-1 <i>H</i> -1,5-benzodiazepines 180 (a-e) under (MWI) method | 68 |
| 2.31 | Synthesis of 2,4-disubstituted 1,5-benzodiazepine derivatives 182 (a-o) under (MWI) method | 68 |
| 2.32 | Synthesis of 1,5-benzodiazepine derivatives (184) in the presence of sulfated zirconia as catalyst | 69 |
| 2.33 | Synthesis of 1,5-benzodiazepine derivatives (186) in the presence of 2,4,6-trichloro-1,3,5-triazine (TCT) as catalyst | 69 |
| 2.34 | Synthesis of 1,5-benzodiazepine derivatives (189) from 2-arylidine-1,3-diketones | 70 |
| 2.35 | Synthesis of 1,5-benzodiazepine derivatives (192) from β -ketoester | 70 |
| 2.36 | Synthesis of 1,5-benzodiazepine derivatives (194) from β -aminoketons | 71 |
| 2.37 | Synthesis of 1,5-benzodiazepin-2-one derivatives (199-202) α,β -unsaturated carboxylic acid | 72 |
| 2.38 | Synthesis of 5-substituted 1,5-benzodiazepin-2-ones derivatives (204-209) | 73 |
| 2.39 | Synthesis of 2,3-dihydro-1 <i>H</i> -1,5-benzodiazepine derivatives (212) | 73 |
| 2.40 | Synthesis of 2,3-dihydro-1 <i>H</i> -1,5-benzodiazepine derivatives (215) | 74 |
| 3.1 | Synthesis of 3-acetyl-2,5-dichlorothiophene (246) and 2-acetyl-5-chlorothiophene (247) | 92 |
| 3.2 | Synthesis of heterocyclic chalcones (250-255) | 93 |
| 3.3 | Illustrated the synthesis of chalcones (250-252) by the | 94 |

| | | |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| | base-catalyzed mechanism (Claisen-Schmidt reaction) | |
| 3.4 | Synthesis of heterocyclic chalcones (264-271) | 100 |
| 3.5 | Synthesis of heterocyclic chalcones (272-278) | 106 |
| 3.6 | Synthesis of pyrazoline derivatives (279-284) | 113 |
| 3.7 | Synthesis of pyrazoline derivatives (285-292) | 118 |
| 3.8 | Proposed mechanism for the synthesis of pyrazoline derivatives (285-292) | 120 |
| 3.9 | Synthesis of pyrazoline derivatives (293-299) | 126 |
| 3.10 | Synthetic route followed for the synthesis of titled 1,5-benzodiazepine derivatives (316-331) | 133 |
| 3.11 | The proposed mechanism for the synthesis of 4-methyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one (199) and synthesis of substituted 1,5-benzodiazepines (316-331) | 134 |

LIST OF ABBREVIATIONS

| | |
|------------------------------------|------------------------------------------------------------|
| CH ₃ CO ₂ H | - Acetic Acid |
| Ac | - Acetyl |
| AIDS | - Acquired Immunodeficiency Syndrome |
| α | - Alpha |
| Al ₂ O ₃ | - Alumina |
| AlCl ₃ | - Aluminum Chloride |
| ARVs | - Antiretrovirals |
| ART | - Antiretroviral Therapy |
| aq | - Aqueous |
| AA | - Ascorbic Acid |
| ATR-IR | - Attenuated Total Reflectance- Infrared - |
| AZT | - Azidothymidine |
| ABTS | - 2,2'-Azino-bis-(3-ethylbenzothiazoline-6-sulphonic acid) |
| BDZ | - Benzodiazepines |
| β | - Beta |
| H ₃ BO ₃ | - Boric Acid |
| BF ₃ -Et ₂ O | - Boron Trifluoride Ethyl Etherate |
| BHT | - Butylated Hydroxytoluene |
| CdCl ₂ | - Cadmium Chloride |
| CSA | - Camphor Sulphonic Acid |
| ¹³ C | - Carbon-13 |
| ¹³ C NMR | - Carbon Nuclear Magnetic Resonance |
| CNS | - Central Nervous System |
| CAN | - Ceric Ammonium Nitrate |

| | |
|-------------------|-----------------------------------------------------------------------------------|
| δ | - Chemical Shift |
| cpzPtt | - Chimpanzees(<i>Pan troglodytes troglodytes</i>) |
| CHCl ₃ | - Chloroform |
| CD ₄ | - Cluster of Differentiation 4 |
| CC | - Column Chromatography |
| CRIs | - Co-receptor Inhibitors |
| COSY | - Correlation Spectroscopy |
| <i>J</i> | - Coupling Constant |
| COD | - Cycloocta-1,5-diene |
| CYA | - Czapek Yeast Extract Agar |
| CC ₅₀ | - 50% Cytotoxic Concentration |
| DNA | - Deoxyribonucleic Acid |
| DD | - <i>N</i> -Desmethyldiazepam |
| CDCl ₃ | - Deuterated Chloroform |
| D | - Diazepam |
| 1D | - 1 Dimension |
| 2D | - 2 Dimension |
| DMF | - <i>N,N'</i> -Dimethylformamide |
| DMSO | - Dimethyl Sulfoxide |
| MTT | - (3,(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2 <i>H</i> - tetrazolium bromide) |
| DPPH | - 2,2-Diphenyl-1-picrylhydrazyl |
| DEPT | - Distortionless Enhancement by Polarization Transfer |
| d | - Doublet |
| dd | - Doublet of Doublets |
| ddd | - Doublet of Doublet of Doublets |
| ESI-MS | - Electrospray Ionization Mass Spectrometry |
| ELISA | - Enzyme-Linked Immunosorbent Assay |
| EtOH | - Ethanol |
| EtOAc | - Ethyl Acetate |
| FBS | - Fetal Bovine Serum |
| FLC | - Fluconazole |
| FDA | - Food and Drug Administration |

| | |
|---------------------------------------------------|-----------------------------------------------------------------------------|
| FIs | - Fusion Inhibitors |
| g | - Gram |
| CH ₃ CO ₂ H | - Glacial Acetic Acid |
| Hz | - Hertz |
| HMBC | - Heteronuclear Multiple Bond Correlation |
| HMQC | - Heteronuclear Multiple Quantum Coherence |
| HAART. | - Highly Active Antiretroviral Therapy |
| HIV | - Human Immunodeficiency Viruses |
| NH ₂ NH ₂ .H ₂ O | - Hydrazine Monohydrate |
| HCl | - Hydrochloric Acid |
| HEPES | - <i>N</i> -(2-Hydroxyethyl)-piperazine- <i>N'</i> -(2-ethanesulfonic acid) |
| IR | - Infrared |
| IC | - Inhibition Concentration |
| IC ₅₀ | - Inhibition Concentration at 50 % |
| IZ | - Inhibition Zone |
| INIs | - Integrase Inhibitors |
| LiOH.H ₂ O | - Lithium Hydroxide Monohydrate |
| L | - Litre |
| MHz | - Megahertz |
| m.p | - Melting Point |
| <i>m</i> | - <i>Meta</i> |
| MeOH | - Methanol |
| μg/mL | - Microgram Per Millilitre |
| μL | - Microliters |
| μM | - Micro Molar |
| MAOS | - Microwave-Assisted Organic Synthesis |
| MWI | - Microwave Irradiation |
| mL | - Millilitre |
| mm | - Millimetre |
| MIC | - Minimum Inhibitory Concentration |
| min | - Minute (s) |
| m | - Multiplet |

| | |
|-------------------------------------------------------|---------------------------------------------------|
| ng/g | - Nanogram/gram |
| nm | - Nanometer |
| NNRTIs | - Non-nucleoside Reverse Transcriptase Inhibitors |
| N | - Normal |
| NMR | - Nuclear Magnetic Resonance |
| NRTIs | - Nucleoside Reverse Transcriptase Inhibitors |
| NtRTIs | - Nucleotide Reverse Transcriptase Inhibitors |
| NA | - Nutrient Agar |
| NB | - Nutrient Broth |
| <i>o</i> - | - <i>Ortho</i> |
| <i>o</i> -PDA | - <i>Ortho</i> -Phenylenediamine |
| <i>p</i> - | - <i>Para</i> |
| ppm | - Part Per Million |
| C ₆ F ₅ CO ₂ H | - 2,3,4,5,6-Pentafluorobenzoic acid |
| cm ⁻¹ | - Per Centimeter |
| C ₆ H ₅ NHNH ₂ · HCl | - Phenylhydrazine Hydrochloride |
| C ₆ H ₅ NHNHCONH ₂ | - Phenylsemicarbazide |
| PEG | - Polyethylene Glycol |
| K ₂ CO ₃ | - Potassium Carbonate |
| KF | - Potassium Fluoride |
| KOH | - Potassium Hydroxide |
| PIs | - Protease Inhibitors |
| ¹ H | - Proton |
| ¹ H NMR | - Proton Nuclear Magnetic Resonance |
| rRT | - Recombinant Reverse Transcriptase |
| RNA | - Ribonucleic Acid |
| rt | - Room Temperature |
| Sm | - Samarium |
| Sc(OTf) ₃ | - Scandium(III) Triflate |
| sec | - Second (s) |
| H ₂ CONHNH ₂ | - Semicarbazide |
| SiO ₂ | - Silica Gel |
| AgNO ₃ | - Silver Nitrate |

| | |
|---------------------------------------------------------------------|--------------------------------------------------------|
| SIVcpz | - Simian Immunodeficiency Viruses Found in Chimpanzees |
| s | - Singlet |
| CH ₃ COONa | - Sodium Acetate |
| NaOH | - Sodium Hydroxide |
| S.D | - Standard Drug |
| SAR | - Structure Activity Relationship |
| 4-(H ₂ N)C ₆ H ₄ SO ₃ H | - Sulfanilic Acid |
| H ₂ SO ₄ | - Sulphuric Acid |
| TBAB | - Tetrabutylammonium Bromide |
| THF | - Tetrahydrofuran |
| TLC | - Thin Layer Chromatography |
| NH ₂ CSNHNH ₂ | - Thiosemicarbazide |
| TCID | - Tissue Culture Infectious Dose |
| TiCl ₄ | - Titanium (IV) Chloride |
| TCT | - 2,4,6-Trichloro-1,3,5-triazine |
| Et ₃ N | - Triethylamine |
| TEAA | - Triethylammonium Acetate |
| t | - Triplet |
| US | - Ultrasound Irradiation |
| UV | - Ultraviolet |
| UNAIDS | - United Nations Programme on HIV/AIDS |
| H ₂ O | - Water |
| WHO | - World Health Organization |
| Yb(OTf) ₃ | - Ytterbium(III) Triflate |
| ZnO | - Zinc Oxide |
| ZOI | - Zone of Inhibition |

LIST OF APPENDICES

| APPENDIX NO | TITLE | PAGE |
|----------------|-----------------------------------------------------------------------------------------------------------------------|------|
| 1 | IR spectrum of 3-acetyl-2,5-dichloro thiophene (246) | 237 |
| 2 | ¹ H NMR spectrum of 3-acetyl-2,5-dichloro thiophene (246) | 237 |
| 3 | IR spectrum of 2-acetyl-5-chlorothiophene (247) | 238 |
| 4 | ¹ H NMR spectrum of 2-acetyl-5-chloro thiophene (247) | 238 |
| 5 | ¹ H NMR spectrum of 1-(2,5-dichloro thiophen-3-yl)-3-(thiophen-2-yl)-2-propen-1-one (250) | 239 |
| 6 | IR spectrum of 1-(2,5-dichlorothiophen-3-yl)-3-(thiophen-2-yl)-2-propen-1-one (250) | 239 |
| 7 | IR spectrum of 1-(2,5-dichlorothiophen-3-yl)-3-(3-methyl-thiophen-2-yl)-2-propen-1-one (251) | 240 |
| 8 | ¹ H NMR spectrum of 1-(2,5-dichloro thiophen-3-yl)-3-(3-methyl-thiophen-2-yl)-2-propen-1-one (251) | 240 |
| 9 | ¹³ C NMR spectrum of 1-(2,5-dichloro thiophen-3-yl)-3-(3-methyl-thiophen-2-yl)-2-propen-1-one (251) | 241 |
| 10 | DEPT spectra of 1-(2,5-dichlorothiophen-3-yl)-3-(3-methyl-thiophen-2-yl)-2-propen -1-one (251) | 241 |
| 11 | HMQC spectrum of 1-(2,5-dichloro thiophen-3-yl)-3-(3-methyl-thiophen-2-yl)-2-propen-1-one (251) | 242 |
| 12 | Expansion HMQC spectrum of 1-(2,5-dichloro thiophen-3-yl)-3-(3-methyl-thiophen-2-yl)-2-propen-1-one (251) | 242 |
| 13 | HRS-ESI spectrum of (<i>E</i>)-1-(2,5-dichlorothiophen-3-yl)-3-(3-methyl-thiophen-2-yl)-2-propen-1-one (251) | 243 |

| | | |
|----|------------------------------------------------------------------------------------------------------------------------|-----|
| 14 | IR spectrum of 3-(5-bromo-thiophen-2-yl)-1-(2,5-dichlorothiophen-3-yl)-2-propen-1-one (252) | 244 |
| 15 | ¹ H NMR spectrum of 3-(5-bromo-thiophen-2-yl)-1-(2,5-dichlorothiophen-3-yl)-2-propen-1-one (252) | 244 |
| 16 | ¹³ C NMR spectrum of 3-(5-bromo-thiophen-2-yl)-1-(2,5-dichlorothiophen-3-yl)-2-propen-1-one (252) | 245 |
| 17 | DEPT spectra of 3-(5-bromo-thiophen-2-yl)-1-(2,5-dichlorothiophen-3-yl)-2-propen-1-one (252) | 245 |
| 18 | COSY spectrum of 3-(5-bromo-thiophen-2-yl)-1-(2,5-dichlorothiophen-3-yl)-2-propen-1-one (252) | 246 |
| 19 | HMQC spectrum of 3-(5-bromo-thiophen-2-yl)-1-(2,5-dichlorothiophen-3-yl)-2-propen-1-one (252) | 246 |
| 20 | HRS-ESI spectrum of (<i>E</i>)-3-(5-Bromo thiophen-2-yl)-1-(2,5-dichlorothiophen-3-yl)-2-propen-1-one (252) | 247 |
| 21 | IR spectrum of 1-(5-chlorothiophen-2-yl)-3-(thiophen-2-yl)-2-propen-1-one (253) | 248 |
| 22 | ¹ H NMR spectrum of 1-(5-chlorothiophen-2-yl)-3-(thiophen-2-yl)-2-propen-1-one (253) | 248 |
| 23 | IR spectrum of 1-(5-chlorothiophen-2-yl)-3-(3-methyl-thiophen-2-yl)-2-propen-1-one (254) | 249 |
| 24 | ¹ H NMR spectrum of 1-(5-chlorothiophen-2-yl)-3-(3-methyl-thiophen-2-yl)-2-propen-1-one (254) | 249 |
| 25 | ¹³ C NMR spectrum of 1-(5-chloro thiophen-2-yl)-3-(3-methyl-thiophen-2-yl)-2-propen-1-one (254) | 250 |
| 26 | DEPT spectra of 1-(5-chlorothiophen-2-yl)-3-(3-methyl-thiophen-2-yl)-2-propen-1-one (254) | 250 |
| 27 | HMQC spectrum of 1-(5-chlorothiophen-2-yl)-3-(3-methyl-thiophen-2-yl)-2-propen-1-one (254) | 251 |
| 28 | Expansion of HMQC spectrum of 1-(5-chloro thiophen-2-yl)-3-(3-methyl-thiophen-2-yl)-2-propen-1-one (254) | 251 |
| 29 | HRS-ESI spectrum of 1-(5-chloro thiophen-2-yl)-3-(3-methyl-thiophen-2-yl)-2-propen-1-one (254) | 252 |

| | | |
|----|-------------------------------------------------------------------------------------------------------------------------|-----|
| 30 | IR spectrum of 3-(5-bromo-thiophene-2-yl)-1-(5-chlorothiophen-2-yl)-2-propen-1-one (255) | 253 |
| 31 | ¹ H NMR spectrum of 3-(5-bromo-thiophene-2-yl)-1-(5-chlorothiophen-2-yl)-2-propen-1-one (255) | 253 |
| 32 | IR spectrum of (<i>E</i>)-3-(5-bromothiophen-2-yl)-1-phenylprop-2-en-1-one (264) | 254 |
| 33 | ¹ H NMR spectrum of (<i>E</i>)-3-(5-bromo thiophen-2-yl)-1-phenylprop-2-en-1-one (264) | 254 |
| 34 | ¹³ C NMR spectrum of (<i>E</i>)-3-(5-bromo thiophen-2-yl)-1-phenylprop-2-en-1-one (264) | 255 |
| 35 | IR spectrum of (<i>E</i>)-3-(5-bromothiophen-2-yl)-1-(4-chlorophenyl)prop-2-en-1-one (264) | 256 |
| 36 | ¹ H NMR spectrum of (<i>E</i>)-3-(5-bromo thiophen-2-yl)-1-(4-chlorophenyl)prop-2-en-1-one (265) | 256 |
| 37 | ¹³ C NMR spectrum of (<i>E</i>)-3-(5-bromo thiophen-2-yl)-1-(4-chlorophenyl)prop-2-en-1-one (265) | 257 |
| 38 | DEPT spectra of (<i>E</i>)-3-(5-bromothiophen-2-yl)-1-(4-chlorophenyl)prop-2-en-1-one (265) | 257 |
| 39 | COSY spectrum of (<i>E</i>)-3-(5-bromo thiophen-2-yl)-1-(4-chlorophenyl)prop-2-en-1-one (265) | 258 |
| 40 | HMQC spectrum of (<i>E</i>)-3-(5-bromo thiophen-2-yl)-1-(4-chlorophenyl)prop-2-en-1-one (265) | 258 |
| 41 | Expansion HMQC spectrum of (<i>E</i>)-3-(5-bromo thiophen-2-yl)-1-(4-chlorophenyl) prop-2-en-1-one (265) | 259 |
| 42 | HMBC spectrum of (<i>E</i>)-3-(5-bromo thiophen-2-yl)-1-(4-chlorophenyl)prop-2-en-1-one (265) | 259 |
| 43 | IR spectrum of (<i>E</i>)-3-(5-bromothiophen-2-yl)-1-(4-fluorophenyl)prop-2-en-1-one (266) | 260 |
| 44 | ¹ H NMR spectrum of (<i>E</i>)-3-(5-bromo thiophen-2-yl)-1-(4-fluorophenyl)prop-2-en-1-one (266) | 260 |
| 45 | ¹³ C NMR spectrum of (<i>E</i>)-3-(5-bromo thiophen-2-yl)-1-(4-fluorophenyl)prop-2-en-1-one (266) | 261 |

| | | |
|----|-------------------------------------------------------------------------------------------------------------------------------------|-----|
| 46 | Expansion ¹³ C NMR spectrum of (<i>E</i>)-3-(5-bromo thiophen-2-yl)-1-(4-fluorophenyl) prop-2-en-1-one (266) | 261 |
| 47 | IR spectrum of (<i>E</i>)-1-(4-bromophenyl)-3-(5-bromo thiophen-2-yl)prop-2-en-1-one (267) | 262 |
| 48 | ¹ H NMR spectrum of (<i>E</i>)-1-(4-bromo phenyl)-3-(5-bromothiophen-2-yl)prop-2-en-1-one (267) | 262 |
| 49 | ¹³ C NMR spectrum of (<i>E</i>)-1-(4-bromo phenyl)-3-(5-bromothiophen-2-yl)prop-2-en-1-one (267) | 263 |
| 50 | IR spectrum of (<i>E</i>)-3-(5-bromothiophen-2-yl)-1-(4-iodophenyl)prop-2-en-1-one (268) | 263 |
| 51 | ¹ H NMR spectrum of (<i>E</i>)-3-(5-bromo thiophen-2-yl)-1-(4-iodophenyl)prop-2-en-1-one (268) | 264 |
| 52 | ¹³ C NMR spectrum of (<i>E</i>)-3-(5-bromo thiophen-2-yl)-1-(4-iodophenyl)prop-2-en-1-one (268) | 264 |
| 53 | IR spectrum of (<i>E</i>)-3-(5-bromothiophen-2-yl)-1-(4-methoxyphenyl)prop-2-en-1-one (269) | 265 |
| 54 | ¹ H NMR spectrum of (<i>E</i>)-3-(5-bromo thiophen-2-yl)-1-(4-methoxyphenyl)prop-2-en-1-one (269) | 265 |
| 55 | ¹³ C NMR spectrum of (<i>E</i>)-3-(5-bromo thiophen-2-yl)-1-(4-methoxyphenyl)prop-2-en-1-one (269) | 266 |
| 56 | IR spectrum of (<i>E</i>)-3-(5-bromothiophen-2-yl)-1- <i>p</i> -tolylprop-2-en-1-one (270) | 266 |
| 57 | ¹ H NMR spectrum of (<i>E</i>)-3-(5-bromo thiophen-2-yl)-1- <i>p</i> -tolylprop-2-en-1-one (270) | 267 |
| 58 | ¹³ C NMR spectrum of (<i>E</i>)-3-(5-bromo thiophen-2-yl)-1- <i>p</i> -tolylprop-2-en-1-one (270) | 267 |
| 59 | IR spectrum of (<i>E</i>)-3-(5-bromothiophen-2-yl)-1-(4-nitrophenyl)prop-2-en-1-one (271) | 268 |
| 60 | ¹ H NMR spectrum of (<i>E</i>)-3-(5-bromo thiophen-2-yl)-1-(4-nitrophenyl)prop-2-en-1-one (271) | 268 |
| 61 | ¹³ C NMR spectrum of (<i>E</i>)-3-(5-bromo thiophen-2-yl)-1-(4-nitrophenyl)prop-2-en-1-one (271) | 269 |

| | | |
|----|--------------------------------------------------------------------------------------------------------------------------|-----|
| 62 | IR spectrum of (<i>E</i>)-3-(3-methylthiophen-2-yl)-1-phenylprop-2-en-1-one (272) | 269 |
| 63 | ¹ H NMR spectrum of (<i>E</i>)-3-(3-methyl thiophen-2-yl)-1-phenylprop-2-en-1-one (272) | 270 |
| 64 | ¹³ C NMR spectrum of (<i>E</i>)-3-(3-methylthiophen-2-yl)-1-phenylprop-2-en-1-one (272) | 270 |
| 65 | IR spectrum of (<i>E</i>)-1-(4-chlorophenyl)-3-(3-methylthiophen-2-yl)prop-2-en-1-one (273) | 271 |
| 66 | ¹ H NMR spectrum of (<i>E</i>)-1-(4-chloro phenyl)-3-(3-methylthiophen-2-yl)prop-2-en-1-one (273) | 271 |
| 67 | ¹³ C NMR spectrum of (<i>E</i>)-1-(4-chloro phenyl)-3-(3-methylthiophen-2-yl)prop-2-en-1-one (273) | 272 |
| 68 | IR spectrum of (<i>E</i>)-1-(4-fluorophenyl)-3-(3-methylthiophen-2-yl)prop-2-en-1-one (274) | 272 |
| 69 | ¹ H NMR spectrum of (<i>E</i>)-1-(4-fluoro phenyl)-3-(3-methylthiophen-2-yl)prop-2-en-1-one (274) | 273 |
| 70 | ¹³ C NMR spectrum of (<i>E</i>)-1-(4-fluoro phenyl)-3-(3-methylthiophen-2-yl)prop-2-en-1-one (274) | 273 |
| 71 | IR spectrum of (<i>E</i>)-1-(4-bromophenyl)-3-(3-methylthiophen-2-yl)prop-2-en-1-one (275) | 274 |
| 72 | ¹ H NMR spectrum of (<i>E</i>)-1-(4-bromo phenyl)-3-(3-methylthiophen-2-yl)prop-2-en-1-one (275) | 274 |
| 73 | ¹³ C NMR spectrum of (<i>E</i>)-1-(4-bromo phenyl)-3-(3-methylthiophen-2-yl)prop-2-en-1-one (275) | 275 |
| 74 | IR spectrum of (<i>E</i>)-1-(4-iodophenyl)-3-(3-methylthiophen-2-yl)prop-2-en-1-one (276) | 275 |
| 75 | ¹ H NMR spectrum of (<i>E</i>)-1-(4-iodophenyl)-3-(3-methylthiophen-2-yl)prop-2-en-1-one (276) | 276 |
| 76 | ¹³ C NMR spectrum of (<i>E</i>)-1-(4-iodo phenyl)-3-(3-methylthiophen-2-yl)prop-2-en-1-one (276) | 276 |
| 77 | DEPT spectra of (<i>E</i>)-1-(4-iodophenyl)-3-(3-methylthiophen-2-yl)prop-2-en-1-one (276) | 277 |
| 78 | COSY spectrum of (<i>E</i>)-1-(4-iodophenyl)-3-(3-methyl | 277 |

| | | |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| | thiophen-2-yl)prop-2-en-1-one (276) | |
| 79 | HMQC spectrum of (<i>E</i>)-1-(4-iodophenyl)-3-(3-methylthiophen-2-yl)prop-2-en-1-one (276) | 278 |
| 80 | Expansion HMQC spectrum of (<i>E</i>)-1-(4-iodophenyl)-3-(3-methylthiophen-2-yl)prop-2-en-1-one (276) | 278 |
| 81 | HMBC spectrum of (<i>E</i>)-1-(4-iodophenyl)-3-(3-methylthiophen-2-yl)prop-2-en-1-one (276) | 279 |
| 82 | Expansion HMBC spectrum of (<i>E</i>)-1-(4-iodophenyl)-3-(3-methylthiophen-2-yl)prop-2-en-1-one (276) | 279 |
| 83 | IR spectrum of (<i>E</i>)-3-(3-methylthiophen-2-yl)-1- <i>p</i> -tolylprop-2-en-1-one (277) | 280 |
| 84 | ¹ H NMR spectrum of (<i>E</i>)-3-(3-methyl thiophen-2-yl)-1- <i>p</i> -tolylprop-2-en-1-one (277) | 280 |
| 85 | ¹³ C NMR spectrum of (<i>E</i>)-3-(3-methyl thiophen-2-yl)-1- <i>p</i> -tolylprop-2-en-1-one (277) | 281 |
| 86 | IR spectrum of (<i>E</i>)-3-(3-methylthiophen-2-yl)-1-(4-nitrophenyl)prop-2-en-1-one (278) | 281 |
| 87 | ¹ H NMR spectrum of (<i>E</i>)-3-(3-methyl thiophen-2-yl)-1-(4-nitrophenyl)prop-2-en-1-one (278) | 282 |
| 88 | ¹³ C NMR spectrum of (<i>E</i>)-3-(3-methyl thiophen-2-yl)-1-(4-nitrophenyl)prop-2-en-1-one (278) | 282 |
| 89 | IR spectrum of 1-(3-(2,5-dichlorothiophen-3-yl)-5-(thiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1yl)ethanone (279) | 283 |
| 90 | ¹ H NMR spectrum of 1-(3-(2,5-dichloro thiophen-3-yl)-5-(thiophen-2-yl)-4,5-di hydro-1 <i>H</i> -pyrazol-1yl)ethanone (279) | 283 |
| 91 | ¹³ C NMR spectrum of 1-(3-(2,5-dichlorothiophen-3-yl)-5-(thiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1yl)ethanone (279) | 284 |
| 92 | IR spectrum of 1-(3-(2,5-dichlorothiophen-3-yl)-5-(3-methylthiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (280) | 284 |

| | | |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 93 | ¹ H NMR spectrum of 1-(3-(2,5-dichloro thiophen-3-yl)-5-(3-methylthiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (280) | 285 |
| 94 | ¹³ C NMR spectrum of 1-(3-(2,5-dichloro thiophen-3-yl)-5-(3-methylthiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (280) | 285 |
| 95 | IR spectrum of 1-(5-(5-bromothiophen-2-yl)-3-(2,5-dichlorothiophen-3-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (281) | 286 |
| 96 | ¹ H NMR spectrum of 1-(5-(5-bromo thiophen-2-yl)-3-(2,5-dichlorothiophen-3-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (281) | 286 |
| 97 | ¹³ C NMR spectrum of 1-(5-(5-bromo thiophen-2-yl)-3-(2,5-dichlorothiophen-3-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (281) | 287 |
| 98 | IR spectrum of 1-(3-(5-chlorothiophen-2-yl)-5-(thiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (282) | 287 |
| 99 | ¹ H NMR spectrum of 1-(3-(5-chloro thiophen-2-yl)-5-(thiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (282) | 288 |
| 100 | ¹³ C NMR spectrum of 1-(3-(5-chloro thiophen-2-yl)-5-(thiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (282) | 288 |
| 101 | IR spectrum of 1-(3-(5-chlorothiophen-2-yl)-5-(3-methylthiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (283) | 289 |
| 102 | ¹ H NMR spectrum of 1-(3-(5-chloro thiophen-2-yl)-5-(3-methylthiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (283) | 289 |
| 103 | ¹³ C NMR spectrum of 1-(3-(5-chloro thiophen-2-yl)-5-(3-methylthiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (283) | 290 |

| | | |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 104 | DEPT spectra of 1-(3-(5-chlorothiophen-2-yl)-5-(3-methylthiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (283) | 290 |
| 105 | COSY spectrum of 1-(3-(5-chloro thiophen-2-yl)-5-(3-methylthiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (283) | 291 |
| 106 | Expansion COSY spectrum of 1-(3-(5-chloro thiophen-2-yl)-5-(3-methylthiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (283) | 291 |
| 107 | HMQC spectrum of 1-(3-(5-chloro thiophen-2-yl)-5-(3-methylthiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (283) | 292 |
| 108 | Expansion HMQC spectrum of 1-(3-(5-chloro thiophen-2-yl)-5-(3-methylthiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (283) | 292 |
| 109 | HMBC spectrum of 1-(3-(5-chloro thiophen-2-yl)-5-(3-methylthiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (283) | 293 |
| 110 | Expansion HMBC spectrum of 1-(3-(5-chloro thiophen-2-yl)-5-(3-methylthiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (283) | 293 |
| 111 | IR spectrum of 1-(5-(5-bromothiophen-2-yl)-3-(5-chlorothiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (284) | 294 |
| 112 | ¹ H NMR spectrum of 1-(5-(5-bromo thiophen-2-yl)-3-(5-chlorothiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (284) | 294 |
| 113 | ¹³ C NMR spectrum of 1-(5-(5-bromo thiophen-2-yl)-3-(5-chlorothiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (284) | 295 |
| 114 | IR spectrum of 1-(5-(5-bromothiophen-2-yl)-3-phenyl-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (285) | 295 |
| 115 | ¹ H NMR spectrum of 1-(5-(5-bromo thiophen-2-yl)- | 296 |

| | | |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| | 3-phenyl-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (285) | |
| 116 | ¹³ C NMR spectrum of 1-(5-(5-bromo thiophen-2-yl)- 3-phenyl-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (285) | 296 |
| 117 | IR spectrum of 1-(5-(5-bromothiophen-2-yl)-3-(4- chlorophenyl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (286) | 297 |
| 118 | ¹ H NMR spectrum of 1-(5-(5-bromo thiophen-2- yl)-3-(4-chlorophenyl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl) ethanone (286) | 297 |
| 119 | ¹³ C NMR spectrum of 1-(5-(5-bromo thiophen-2-yl)- 3-(4-chlorophenyl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl) ethanone (286) | 298 |
| 120 | IR spectrum of 1-(5-(5-bromothiophen-2-yl)-3-(4- fluorophenyl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (287) | 298 |
| 121 | ¹ H NMR spectrum of 1-(5-(5-bromo thiophen-2-yl)- 3-(4-fluorophenyl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl) ethanone (287) | 299 |
| 122 | ¹³ C NMR spectrum of 1-(5-(5-bromo thiophen-2-yl)- 3-(4-fluorophenyl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl) ethanone (287) | 299 |
| 123 | IR spectrum of 1-(3-(4-bromophenyl)-5-(5-bromo thiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (288) | 300 |
| 124 | ¹ H NMR spectrum of 1-(3-(4-bromo phenyl)-5-(5- bromothiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl) ethanone (288) | 300 |
| 125 | ¹³ C NMR spectrum of 1-(3-(4-bromo phenyl)-5-(5- bromothiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl) ethanone (288) | 301 |
| 126 | IR spectrum of 1-(5-(5-bromothiophen-2-yl)-3-(4- | 301 |

| | | |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| | iodophenyl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (289) | |
| 127 | ¹ H NMR spectrum of 1-(5-(5-bromo thiophen-2-yl)- 3-(4-iodophenyl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl) ethanone (289) | 302 |
| 128 | ¹³ C NMR spectrum of 1-(5-(5-bromo thiophen-2-yl)- 3-(4-iodophenyl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl) ethanone (289) | 302 |
| 129 | IR spectrum of 1-(5-(5-bromothiophen-2-yl)-3-(4- methoxyphenyl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl) ethanone (290) | 303 |
| 130 | ¹ H NMR spectrum of 1-(5-(5-bromo thiophen-2-yl)- 3-(4-methoxyphenyl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl) ethanone (290) | 303 |
| 131 | ¹³ C NMR spectrum of 1-(5-(5-bromo thiophen-2-yl)- 3-(4-methoxyphenyl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl) ethanone (290) | 304 |
| 132 | IR spectrum of 1-(5-(5-bromothiophen-2-yl)-3- <i>p</i> - tolyl-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (291) | 304 |
| 133 | ¹ H NMR spectrum of 1-(5-(5-bromo thiophen-2-yl)- 3- <i>p</i> -tolyl-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (291) | 305 |
| 134 | ¹³ C NMR spectrum of 1-(5-(5-bromo thiophen-2-yl)- 3- <i>p</i> -tolyl-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (291) | 305 |
| 135 | IR spectrum of 1-(5-(5-bromothiophen-2-yl)-3-(4- nitrophenyl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (292) | 306 |
| 136 | ¹ H NMR spectrum of 1-(5-(5-bromo thiophen-2-yl)- 3-(4-nitrophenyl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl) ethanone (292) | 306 |
| 137 | ¹³ C NMR spectrum of 1-(5-(5-bromo thiophen-2-yl)- 3-(4-nitrophenyl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl) | 307 |

| | | |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------|-----|
| | ethanone (292) | |
| 138 | DEPT spectra of 1-(5-(5-bromothiophen-2-yl)-3-(4-nitrophenyl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (292) | 307 |
| 139 | COSY spectrum of 1-(5-(5-bromo thiophen-2-yl)-3-(4-nitrophenyl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (292) | 308 |
| 140 | HMQC spectrum of 1-(5-(5-bromo thiophen-2-yl)-3-(4-nitrophenyl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (292) | 308 |
| 141 | HMBC spectrum of 1-(5-(5-bromo thiophen-2-yl)-3-(4-nitrophenyl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (292) | 309 |
| 142 | IR spectrum of 1-(5-(3-methylthiophen-2-yl)-3-phenyl-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (293) | 310 |
| 143 | ¹ H NMR spectrum of 1-(5-(3-methyl thiophen-2-yl)-3-phenyl-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (293) | 310 |
| 144 | ¹³ C NMR spectrum of 1-(5-(3-methyl thiophen-2-yl)-3-phenyl-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (293) | 311 |
| 145 | IR spectrum of 1-(3-(4-chlorophenyl)-5-(3-methylthiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (294) | 311 |
| 146 | ¹ H NMR spectrum of 1-(3-(4-chloro phenyl)-5-(3-methylthiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (294) | 312 |
| 147 | ¹³ C NMR spectrum of 1-(3-(4-chloro phenyl)-5-(3-methylthiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (294) | 312 |
| 148 | IR spectrum of 1-(3-(4-fluorophenyl)-5-(3-methylthiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (295) | 313 |

| | | |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 149 | ¹ H NMR spectrum of 1-(3-(4-fluorophenyl)-5-(3-methylthiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (295) | 313 |
| 150 | ¹³ C NMR spectrum of 1-(3-(4-fluoro phenyl)-5-(3-methylthiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (295) | 314 |
| 151 | IR spectrum of 1-(3-(4-bromophenyl)-5-(3-methylthiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (296) | 314 |
| 152 | ¹ H NMR spectrum of 1-(3-(4-bromo phenyl)-5-(3-methylthiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (296) | 315 |
| 153 | ¹³ C NMR spectrum of 1-(3-(4-bromo phenyl)-5-(3-methylthiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (296) | 315 |
| 154 | IR spectrum of 1-(3-(4-iodophenyl)-5-(3-methylthiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (297) | 316 |
| 155 | ¹ H NMR spectrum of 1-(3-(4-iodophenyl)-5-(3-methylthiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (297) | 316 |
| 156 | ¹³ C NMR spectrum of 1-(3-(4-iodop henyl)-5-(3-methylthiophen-2-yl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (297) | 317 |
| 157 | IR spectrum of 1-(5-(3-methylthiophen-2-yl)-3- <i>p</i> -tolyl-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (298) | 317 |
| 158 | ¹ H NMR spectrum of 1-(5-(3-methyl thiophen-2-yl)-3- <i>p</i> -tolyl-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (298) | 318 |
| 159 | ¹³ C NMR spectrum of 1-(5-(3-methyl thiophen-2-yl)-3- <i>p</i> -tolyl-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (298) | 318 |
| 160 | DEPT spectra of 1-(5-(3-methylthiophen-2-yl)-3- <i>p</i> - | 319 |

| | | |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------|-----|
| | tolyl-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (298) | |
| 161 | COSY spectrum of 1-(5-(3-methyl thiophen-2-yl)-3- <i>p</i> -tolyl-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (298) | 319 |
| 162 | HMQC spectrum of 1-(5-(3-methyl thiophen-2-yl)-3- <i>p</i> -tolyl-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (298) | 320 |
| 163 | HMBC spectrum of 1-(5-(3-methyl thiophen-2-yl)-3- <i>p</i> -tolyl-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (298) | 320 |
| 164 | Expansion of HMBC spectrum of 1-(5-(3-methyl thiophen-2-yl)-3- <i>p</i> -tolyl-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (298) | 321 |
| 165 | IR spectrum of 1-(5-(3-methylthiophen-2-yl)-3-(4-nitrophenyl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (299) | 322 |
| 166 | ¹ H NMR spectrum of 1-(5-(3-methyl thiophen-2-yl)-3-(4-nitrophenyl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (299) | 322 |
| 167 | ¹³ C NMR spectrum of 1-(5-(3-methyl thiophen-2-yl)-3-(4-nitrophenyl)-4,5-dihydro-1 <i>H</i> -pyrazol-1-yl)ethanone (299) | 323 |
| 168 | IR spectrum of 4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (199) | 324 |
| 169 | ¹ H NMR spectrum of 4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (199) | 324 |
| 170 | IR spectrum of 5-(benzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (316) | 325 |
| 171 | ¹ H NMR spectrum of 5-(benzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (316) | 325 |
| 172 | ¹³ C NMR spectrum of 5-(benzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (316) | 326 |
| 173 | IR spectrum of 5-(2-chlorobenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (317) | 326 |
| 174 | ¹ H NMR spectrum of 5-(2-chlorobenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (317) | 327 |

| | | |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 175 | Expansion of ¹ H NMR spectrum of 5-(2-chloro benzoyl)-4-methyl-1,3,4,5-tetra hydro-2 <i>H</i> -1,5-benzodiazepin-2-one (317) | 327 |
| 176 | ¹³ C NMR spectrum of 5-(2-chloro benzoyl)-4-methyl -1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (317) | 328 |
| 177 | IR spectrum of 5-(3-chlorobenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (318) | 328 |
| 178 | ¹ H NMR spectrum of 5-(3-chlorobenzoyl) -4-methyl -1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (318) | 329 |
| 179 | Expansion of ¹ H NMR spectrum of 5-(3-chlorobenzoyl)-4-methyl-1,3,4,5-tetra hydro-2 <i>H</i> -1,5-benzodiazepin-2-one (318) | 329 |
| 180 | ¹³ C NMR spectrum of 5-(3-chlorobenzoyl)-4-methyl -1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (318) | 330 |
| 181 | IR spectrum of 5-(4-chlorobenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (319) | 330 |
| 182 | ¹ H NMR spectrum of 5-(4-chlorobenzoyl)-4-methyl -1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (319) | 331 |
| 183 | Expansion of ¹ H NMR spectrum of 5-(4-chlorobenzoyl)-4-methyl-1,3,4,5-tetra hydro-2 <i>H</i> -1,5-benzodiazepin-2-one (319) | 331 |
| 184 | ¹³ C NMR spectrum of 5-(4-chlorobenzoyl)-4-methyl -1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (319) | 332 |
| 185 | IR spectrum of 5-(2-fluorobenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (320) | 332 |
| 186 | ¹ H NMR spectrum of 5-(2-fluorobenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (320) | 333 |
| 187 | Expansion of ¹ H NMR spectrum of 5-(2-fluorobenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (320) | 333 |

| | | |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| | yl)-4-methyl-1,3,4,5-tetra hydro-2 <i>H</i> -1,5-benzodi azepin-2-one (320) | |
| 188 | ¹³ C NMR spectrum of 5-(2-fluoro benzoyl)-4-methyl -1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (320) | 334 |
| 189 | IR spectrum of 5-(3-fluorobenzoyl)-4-methyl-1,3,4,5- tetrahydro-2 <i>H</i> -1,5-benzo diazepin-2-one (321) | 334 |
| 190 | ¹ H NMR spectrum of 5-(3-fluorobenzoyl)-4-methyl- 1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (321) | 335 |
| 191 | Expansion of ¹ H NMR spectrum of 5-(3-fluorobenzo yl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodi azepin-2-one (321) | 335 |
| 192 | ¹³ C NMR spectrum of 5-(3-fluorobenzoyl) -4-methyl -1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzo diazepin-2-one (321) | 336 |
| 193 | IR spectrum of 5-(4-fluorobenzoyl)-4-methyl-1,3,4,5- tetrahydro-2 <i>H</i> -1,5-benzo diazepin-2-one (322) | 336 |
| 194 | ¹ H NMR spectrum of 5-(4-fluorobenzoyl)-4-methyl- 1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (322) | 337 |
| 195 | Expansion of ¹ H NMR spectrum of 5-(4-fluorobenzo yl)-4-methyl-1,3,4,5-tetra hydro-2 <i>H</i> -1,5-benzodi azepin-2-one (322) | 337 |
| 196 | ¹³ C NMR spectrum of 5-(4-fluorobenzoyl)-4-methyl -1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (322) | 338 |
| 197 | IR spectrum of 5-(2-bromobenzoyl)-4-methyl-1,3,4 ,5 -tetrahydro-2 <i>H</i> -1,5-benzo diazepin-2-one (323) | 338 |
| 198 | ¹ H NMR spectrum of 5-(2-bromobenzoyl)-4-methyl- 1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzo diazepin-2-one (323) | 339 |
| 199 | Expansion of ¹ H NMR spectrum of 5-(2-bromo benzo yl)-4-methyl-1,3,4,5-tetra hydro-2 <i>H</i> -1,5-benzodi azepin-2-one (323) | 339 |

| | | |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 200 | ¹³ C NMR spectrum of 5-(2-bromobenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (323) | 340 |
| 201 | IR spectrum of 5-(3-bromobenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (324) | 340 |
| 202 | ¹ H NMR spectrum of 5-(3-bromobenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (324) | 341 |
| 203 | Expansion of ¹ H NMR spectrum of 5-(3-bromobenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (324) | 341 |
| 204 | ¹³ C NMR spectrum of 5-(3-bromobenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (324) | 342 |
| 205 | IR spectrum of 5-(4-bromobenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (325) | 342 |
| 206 | ¹ H NMR spectrum of 5-(4-bromobenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (325) | 343 |
| 207 | Expansion of ¹ H NMR spectrum of 5-(4-bromobenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (325) | 343 |
| 208 | ¹³ C NMR spectrum of 5-(4-bromobenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (325) | 344 |
| 209 | IR spectrum of 5-(2-methoxybenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (326) | 344 |
| 210 | ¹ H NMR spectrum of 5-(2-methoxybenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (326) | 345 |
| 211 | Expansion of ¹ H NMR spectrum of 5-(2-methoxybenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (326) | 345 |

| | | |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 212 | ¹³ C NMR spectrum of 5-(2-methoxybenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (326) | 346 |
| 213 | IR spectrum of 5-(3-methoxybenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (327) | 346 |
| 214 | ¹ H NMR spectrum of 5-(3-methoxybenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (327) | 347 |
| 215 | Expansion of ¹ H NMR spectrum of 5-(3-methoxybenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (327) | 347 |
| 216 | ¹³ C NMR spectrum of 5-(3-methoxybenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (327) | 348 |
| 217 | IR spectrum of 5-(4-methoxybenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (328) | 348 |
| 218 | ¹ H NMR spectrum of 5-(4-methoxybenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (328) | 349 |
| 219 | Expansion of ¹ H NMR spectrum of 5-(4-methoxybenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (328) | 349 |
| 220 | ¹³ C NMR spectrum of 5-(4-methoxybenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (328) | 350 |
| 221 | DEPT spectra of 5-(4-methoxybenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (328) | 350 |
| 222 | COSY spectrum of 5-(4-methoxybenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (328) | 351 |
| 223 | Expansion of COSY spectrum of 5-(4-methoxybenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (328) | 351 |

| | | |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 224 | HMQC spectrum of 5-(4-methoxybenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (328) | 352 |
| 225 | Expansion of HMQC spectrum of 5-(4-methoxybenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (328) | 352 |
| 226 | HMBC spectrum of 5-(4-methoxybenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (328) | 353 |
| 227 | Expansion of HMBC spectrum of 5-(4-methoxybenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (328) | 353 |
| 228 | IR spectrum of 5-(2-methylbenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (329) | 354 |
| 229 | ¹ H NMR spectrum of 5-(2-methylbenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (329) | 354 |
| 230 | Expansion of ¹ H NMR spectrum of 5-(2-methylbenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (329) | 355 |
| 231 | ¹³ C NMR spectrum of 5-(2-methylbenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (329) | 355 |
| 232 | IR spectrum of 5-(3-methylbenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (330) | 356 |
| 233 | ¹ H NMR spectrum of 5-(3-methylbenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (330) | 356 |
| 234 | Expansion of ¹ H NMR spectrum of 5-(3-methylbenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (330) | 357 |
| 235 | ¹³ C NMR spectrum of 5-(3-methylbenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (330) | 357 |

| | | |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 236 | IR spectrum of 5-(4-methylbenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (331) | 358 |
| 237 | ¹ H NMR spectrum of 5-(4-methylbenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (331) | 358 |
| 238 | Expansion of ¹ H NMR spectrum of 5-(4-methylbenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (331) | 359 |
| 239 | ¹³ C NMR spectrum of 5-(4-methylbenzoyl)-4-methyl-1,3,4,5-tetrahydro-2 <i>H</i> -1,5-benzodiazepin-2-one (331) | 359 |

CHAPTER 1

INTRODUCTION

1.1 Background of Study

Organic chemistry has a wide range of applications in various fields such as biology, medicine and pharmacology, polymer technology, agriculture and petroleum engineering (Carey and Sundberg, 2000).

Heterocyclic chemistry is one of the branches in organic chemistry. The heterocyclic compounds contain atom either one or more atom in addition to carbon, such as nitrogen, oxygen or sulphur (Morrison and Boyd, 2002). The heterocyclic compounds provide a wide range of biological activities especially in medicine or pharmaceutical chemistry and industrial applications such as construction and agriculture. In addition heterocyclic chemistry plays important role in our life (Katritzky *et al.*, 2010).

Chalcones and heterocyclic chalcone derivatives play important roles against diverse human diseases like as anti-inflammatory (Won *et al.*, 2005); (Vogel *et al.*, 2010); anti-leishmanial (Kayser and Kiderlen, 2001); (Aponte *et al.*, 2010); (De Mello *et al.*, 2014); anti-malarial (Wu *et al.*, 2002); (Tadigoppula *et al.*, 2012); anti-fungal (Ameta *et al.*, 2011); anti-oxidant (Ahmad *et al.*, 2011); (Doan and Tran, 2011); anti-cancer (Bandgar *et al.*, 2010); (Syam *et al.*, 2012); anti-AIDS agents (Wu

et al., 2003); (Cheenpracha *et al.*, 2006) and anti-bacterial(Asiri and Khan, 2011); (Nowakowska *et al.*, 2008).

Chalcones are synthesized by condensation between aldehydes and ketones. Chalcone is one of important intermediate in synthesis of five, six and seven membered ring (Kaur and Kishore, 2013) such as isoxazole, pyrazole (five member ring) and thiazine, oxazine (six member ring) (Kalirajan *et al.*, 2009) and benzodiazepine (seven member ring) (Bhatia *et al.*, 2008). In addition chalcones can be used as an intermediate in the biosynthesis of flavonoids (Ávila *et al.*, 2008).

In this work, three series of thiophene chalcones were synthesized from different heterocyclic ketones or aromatic ketones and different heterocyclic aldehydes via base catalyzed Claisen-Schmidt reaction. The thiophene chalcones were subjected to cyclocondensation reaction by using hydrazine hydrate in glacial acetic acid to give three series of *N*-acetylated pyrazoline derivatives.

Pyrazoline moiety is a five membered heterocyclic ring associated with a large number of pharmaceutical properties such as anti-inflammatory (Gökhan-Kelekçi *et al.*, 2007), antifungal (Zhang *et al.*, 2010); (Hassan, 2013); (Oliveira *et al.*, 2014), anti malaria (Bekhit *et al.*, 2012); (Cunico *et al.*, 2006), antibacterial (Dabholkar and Ansari, 2009); (Liu *et al.*, 2014); (Hassan, 2013), antioxidant (Jois *et al.*, 2014) and against depression (Das *et al.*, 2012).

According their biological activities, there are a large number of pyrazoline derivatives using diverse synthetic methods reported in literature. These methods include cyclization of chalcones with diazomethane (Lévai, 1997), aminoguanidine hydrochloride (Dos Santos *et al.*, 2017), thiosemicarbazide (Gomha *et al.*, 2017), phenyl hydrazine (Khan *et al.*, 2014) and semicarbazide (Das *et al.*, 2012).

The next project is synthesis of benzodiazepine derivatives. Benzodiazepines moiety is a seven membered heterocyclic ring attracting widespread attention due to variety of applications and biological activities exhibited by derivatives of this

moiety. They are mostly used in treatment of anxiety, insomnia, muscle spasms and epilepsy (Wildmann *et al.*, 1988). Benzodiazepines derivatives also exhibited cytotoxic activity against human cancer like colon cancer, lung cancer, breast cancer and bladder cancer (Nawrocka *et al.*, 2001a), analgesic, anti-inflammatory (Roma *et al.*, 1991), antileukemic (Krezel and Graczyk, 1998) and antimicrobial (Babu *et al.*, 2014).

1.2 Problem Statement

Fungal infections are considered critical types of health problems infecting humans' health round the world (Turan-Zitouni *et al.*, 2005); (Pilmis *et al.*, 2016); (Campoy and Adrio, 2017); (Revie *et al.*, 2018). There are many available antibiotics for example fluconazole, voriconazole, itraconazole, Posaconazole, micafungin, flucytosine and caspofungin (Nivoix *et al.*, 2008); (Arendrup *et al.*, 2013) that serve in killing, weakening or inhibiting fungi and other microbes. Yet, these drugs lead to the emergence of pathogens that are resistant to pharmaceutical drug (Zervos *et al.*, 1994); (Kathiravan *et al.*, 2012); (Ogundeji *et al.*, 2016); (Campoy and Adrio, 2017); (Revie *et al.*, 2018). Moreover, there are many drugs against fungal but they have side effects such as phlebitis, rash, fever and other gastrointestinal symptoms such as (nausea, vomiting, abdominal and diarrhea) (Torres *et al.*, 2005); (Petrikos and Skiada, 2007); (Kathiravan *et al.*, 2012) and sometimes inactive against certain kinds of fungal microorganisms (Ogundeji *et al.*, 2016). Similarly, human immunodeficiency virus (HIV) epidemic is regarded a serious health problem that effects humans' health worldwide (Singh and Bodiwala, 2010); (Casano *et al.*, 2010); (Maartens *et al.*, 2014). In addition, drug resistance (Carr and Cooper, 2000); (Hopkins *et al.*, 2006); (Breckenridge, 2009); (Sarafianos *et al.*, 2009); (Adamson and Freed, 2010); (Rizvi *et al.*, 2014) and side effects of anti HIV drugs came into the limelight in the world (Breckenridge, 2009). For instance, there are some side effects associated with the combination therapies such as renal failure, hypokalemia, abdominal pain, vomiting, diarrhea, nausea, decrease appetite, rash, headache, fatigue (Chesney *et al.*, 2000); (Portman, 2018) as well as some CAN symptoms such as depression and suicidal ideation (Cihlar and Fordyce, 2016).

So, the emergence of drug resistance in microorganisms and HIV and side effects of drugs are major challenges that scientists face. Such challenges have led to searching , exploring and modifying molecules to get novel antifungal and anti-HIV agents.

Thiophene chalcones with its derivatives carrying 2-acetylated pyrazoline and 1,5-benzodiazepine derivatives are reported to have a broad of significant biological activities including antifungal and anti-HIV, respectively. Taking into consideration the importance of the therapeutic uses of these compounds in treatment of fungal and HIV, it is clear that synthesizing and designing new compounds is needed to be explored for their pharmacological properties, namely being against fungal and HIV.

In this study, four series have been synthesized which are thiophene chalcones with its derivatives and benzodiazepine derivatives. The synthesis of novel compounds identified as thiophene chalcones, 2-acetylated pyrazoline derivatives and substituted 1,5-benzodiazepines and their biological activities against fungal and HIV which have not been reported in any previous work so far. Moreover, some thiophene chalcones (series 2 and 3) have been synthesized but no report on the biological activity against fungal has appeared in the scientific database. The present research for new drugs development used as antifungal and anti-HIV is highly significant as it can potentially help to solve the problems related to existing drugs.

1.3 Objectives of Study

The objectives of this research are :

1. To synthesize heterocyclic ketones by using Friedel-Crafts acylation.
2. To synthesize thiophene chalcones, its derivatives carrying 2-acetylated pyrazoline and 1,5-benzodiazepines derivatives.

3. To characterize the synthetic compounds by spectroscopic techniques.
4. To evaluate the bioactivity of the synthetic compounds using antifungal and anti-HIV-1 RT assays.

1.4 Scope of Study

This thesis is divided into four parts. Part one is focusing on the synthesis of 3-acetyl-2,5-dichlorothiophene and 2-acetyl-5-chlorothiophene as starting material for series one by Friedel-Crafts acylation. Then thiophene chalcones were synthesized through Claisen-Schmidt method in the presence of base catalyst. Part two is focusing on the synthesis of *N*-acetylated pyrazoline derivatives using cyclization of thiophene chalcones with hydrazine hydrate in glacial acetic acid by refluxing. Part three focused on synthesizing 4-methyl-1,3,4,5-tetrahydro-2*H*-1,5-benzodiazepin-2-one as starting material. Then the latter was cyclized with appropriate acid chloride to substituted 1,5-benzodiazepines by refluxing in presence of anhydrous tetrahydrofuran and triethylamine. All these compounds were established using spectroscopic techniques including Nuclear Magnetic Resonance (NMR), Infrared Spectroscopy (IR) and electrospray ionization mass spectrometry (ESI- MS) for series one.

Finally, the biological activities including antifungal of the series (two and three) and anti-HIV-1 RT of 1,5-benzodiazepines derivatives (series four). The antimicrobial activity was evaluated against antifungal by microdilution technique for determination of minimum inhibitory concentration (MIC). Fourteen selected compounds of 1,5-benzodiazepines derivatives were tested against HIV-1 RT, inhibition concentration at 50% (IC₅₀) was calculated using serial dilution method.

1.5 Significance of Study

Many people suffer from some diseases that may result from fungal infections or HIV if they do not take safety and prevention. Multidrug-resistant (fungals and HIV) are well known to have undesirable side effects which can delay recovery and may lead to a relapse of the patient.

Previous studies have been carried out on heterocyclic compounds, especially carrying sulfur as thiophene chalcone (Tomar *et al.*, 2007); (Bag *et al.*, 2009); (Kumar *et al.*, 2013a); (Mazimba, 2015) or a ring containing multiple nitrogen such as pyrazole (Kumar *et al.*, 2013d); (Zayane *et al.*, 2015); (Yusuf and Jain, 2012) or benzodiazepine (Bräse *et al.*, 2002) displayed promising results for fungi or anti-HIV-1 RT. In this study, it was observed that the effect of substituents and type on biological activity either on phenyl ring in series of thiophene chalcones with its derivatives or in a series of benzodiazepines derivatives on benzoyl ring can affect antifungal and anti-HIV activities. A synthesis of these new compounds may lead to bioactive compounds and result into designing other new drugs.

REFERENCES

- Abbas, A. and Naseer, M. M. (2014). Synthesis and anti-inflammatory activity of new *N*-acyl-2-pyrazolines bearing homologous alkyloxy side chains. *Acta Chimica Slovenica*, 61, 792-802.
- Abou-Ouf, A., El-Kerdawy, M., Farghaly, A. and Moustafa, M. (1979). Synthesis of some pyrazolines as schistosomicidal agents. *Journal of drug research. Egypt*, 11, 73-80.
- Adamson, C. S. and Freed, E. O. (2010). Novel approaches to inhibiting HIV-1 replication. *Antiviral research*, 85, 119-141.
- Adel, A.-H., Ahmed, E.-S., Hawata, M. A., Kasem, E. R. and Shabaan, M. T. (2007). Synthesis and antimicrobial evaluation of some chalcones and their derived pyrazoles, pyrazolines, isoxazolines, and 5,6-dihydropyrimidine-2-(1*H*)-thiones. *Monatshefte für Chemie-Chemical Monthly*, 138, 889-897.
- Ahmad, M. R., Sastry, V. G. and Bano, N. (2011). Synthesis and cytotoxic, anti oxidant activity of 1, 3-diphenyl-2-propene-1-one derivatives. *International Journal of ChemTech Research*, 3, 1462-1469.
- Aksoz, B. E. and Ertan, R. (2012). Spectral properties of chalcones ii. *Fabad Journal of Pharmaceutical Sciences*, 37, 205-216.

- Al-Maqtari, H. M. 2011. *Synthesis of some new 4,6-(diheteroaromatic)-3-carbonitrile-2-oxo-1,2-dihydropyridine derivatives*. Master, Al al-Bayt University. Jordan.
- Alex, J. M., Singh, S. and Kumar, R. (2014). 1-acetyl-3,5-diaryl-4,5-dihydro (1*H*) pyrazoles: Exhibiting anticancer activity through intracellular ROS scavenging and the mitochondria-dependent death pathway. *Archiv der Pharmazie Chemistry in Life Science*, 347, 717-727.
- Altıntop, M., Dilek, Abu Mohsen, U., Karaca, H., Canturk, Z. and Ozdemir, A. (2014). Synthesis and evaluation of bis-pyrazoline derivatives as potential antimicrobial agents. *Letters in Drug Design and Discovery*, 11, 1199-1203.
- Ambaye, T. G. (2015). A new approach for the synthesis of chalcone, acetyl pyrazoline and amino pyrimidine bearing 1,3,5- triazine nucleus as potential antimicrobial and antitubercular agent. *Mass Spectrometry and Purification Techniques*, 1, 1-8.
- Ameta, K., Kumar, B. and Rathore, N. S. (2011). Microwave induced improved synthesis of some novel substituted 1,3-diarylpropenones and their antimicrobial activity. *Journal of Chemistry*, 8, 665-670.
- Amoozadeh, A., Malmir, M., Koukabi, N. and Otokesh, S. (2015). Microwave-assisted, solvent free preparation of 1,5-benzodiazepine derivatives using nanomagnetic-supported sulfonic acid as a recyclable and heterogeneous catalyst. *Journal of Chemical Research*, 39, 694-697.
- Aoki, N., Muko, M., Ohta, E. and Ohta, S. (2008). C-Geranylated chalcones from the stems of *Angelica keiskei* with superoxide-scavenging activity. *Journal of Natural Products*, 71, 1308-1310.
- Aponte, J. C., Castillo, D., Estevez, Y., Gonzalez, G., Arevalo, J., Hammond, G. B. and Sauvain, M. (2010). *In vitro* and *in vivo* anti-leishmania activity of

polysubstituted synthetic chalcones. *Bioorganic and Medicinal Chemistry Letters*, 20, 100-103.

Archer, G. A. and Sternbach, L. H. (1968). Chemistry of benzodiazepines. *Chemical Reviews*, 68, 747-784.

Arendrup, M. C., Cuenca-Estrella, M., Lass-Flörl, C. and Hope, W. W. (2013). Breakpoints for antifungal agents: An update from EUCAST focussing on echinocandins against *candida spp.* And triazoles against *aspergillus spp.* *Drug Resistance Updates*, 16, 81-95.

Arts, E. J. and Hazuda, D. J. (2012). HIV-1 antiretroviral drug therapy. *Cold Spring Harbor Perspectives in Medicine*, 4, a007161.

Asiri, A. M. and Khan, S. A. (2011). Synthesis and anti-bacterial activities of a bis-chalcone derived from thiophene and its bis-cyclized products. *Molecules*, 16, 523-531.

Attri, P. and Pal, M. (2010). Simple ammonium ionic liquid catalyses the 1,5-benzodiazepine derivatives under mild conditions. *Green Chemistry Letters and Reviews*, 3, 249-256.

Aversa, M., Ferlazzo, A., Giannetto, P. and Kohnke, F. (1986). A convenient synthesis of novel [1, 2, 4] triazolo [4, 3-a][1,5] benzodiazepine derivatives. *Synthesis*, 1986, 230-231.

Ávila, H. P., Smânia, E. d. F. A., Delle Monache, F. and Smânia, A. (2008). Structure–activity relationship of antibacterial chalcones. *Bioorganic and Medicinal Chemistry*, 16, 9790-9794.

Azarifar, D. and Ghasemnejad, H. (2003). Microwave-assisted synthesis of some 3, 5-arylated 2-pyrazolines. *Molecules*, 8, 642-648.

- Babu, M., Pitchumani, K. and Ramesh, P. (2014). Synthesis of 5-benzyl-4-aryl-octahydro-1h-benzo [b][1,5] diazepin-2-ones as potent antidepressant and antimicrobial agents. *Medicinal Chemistry Research*, 23, 2070-2079.
- Bag, S., Ramar, S. and Degani, M. S. (2009). Synthesis and biological evaluation of α , β -unsaturated ketone as potential antifungal agents. *Medicinal Chemistry Research*, 18, 309-316.
- Bagby, G. J., Amedee, A. M., Siggins, R. W., Molina, P. E., Nelson, S. and Veazey, R. S. (2015). Alcohol and HIV effects on the immune system. *Alcohol Research: Current Reviews*, 37, 287.
- Bajwa, B., Khanna, P. L. and Seshadri, T. (1972). New chromenochalcone bavachromene from the seeds of *psoralea corylifolia*. *Current Science*, 41, 814-815.
- Balakrishna, M. and Kaboudin, B. (2001). A simple and new method for the synthesis of 1,5-benzodiazepine derivatives on a solid surface. *Tetrahedron Letters*, 42, 1127-1129.
- Bandgar, B. P., Gawande, S. S., Bodade, R. G., Totre, J. V. and Khobragade, C. N. (2010). Synthesis and biological evaluation of simple methoxylated chalcones as anticancer, anti-inflammatory and antioxidant agents. *Bioorganic and Medicinal Chemistry*, 18, 1364-1370.
- Baseer, M. A. and Khan, A. J. (2012). An efficient one-pot synthesis of 1,5-benzodiazepine derivatives catalyzed by TBAB under mild conditions. *Journal of Chemistry*, 9, 407-414.
- Bekhit, A. A. and Abdel-Aziem, T. (2004). Design, synthesis and biological evaluation of some pyrazole derivatives as anti-inflammatory-antimicrobial agents. *Bioorganic and Medicinal Chemistry*, 12, 1935-1945.

- Bekhit, A. A., Hymete, A., Asfaw, H. and Bekhit, A. E. D. A. (2012). Synthesis and biological evaluation of some pyrazole derivatives as anti-malarial agents. *Archiv der Pharmazie Chemistry in Life Science*, 345, 147-154.
- Beyhan, N., Kocyigit-Kaymakcioglu, B., Gümürü, S. and Aricioglu, F. (2017). Synthesis and anticonvulsant activity of some 2-pyrazolines derived from chalcones. *Arabian Journal of Chemistry*, 10, S2073-S2081.
- Bhatia, M., Choudhari, P. B., Ingale, K. B. and Zarekar, B. E. (2008). Synthesis, screening and qsar studies of 2, 4-disubstituted 1,5-benzodiazepine derivatives. *Oriental Journal of Chemistry*, 24, 147-152
- Bigdeli, M. A., Mahdavinia, G. H., Jafari, S. and Hazarkhani, H. (2007). Wet 2, 4, 6-trichloro [1, 3, 5] triazine (TCT) an efficient catalyst for synthesis of α , α' -bis (substituted-benzylidene) cycloalkanones under solvent-free conditions. *Catalysis Communications*, 8, 2229-2231.
- Bohm, B. A. (1998). *Introduction to flavonoids*, Amsterdam, The Netherlands: Harwood academic publishers.
- Bräse, S., Gil, C. and Knepper, K. (2002). The recent impact of solid-phase synthesis on medicinally relevant benzoannelated nitrogen heterocycles. *Bioorganic and Medicinal Chemistry*, 10, 2415-2437.
- Breckenridge, A. (2009). Pharmacology of drugs for HIV. *Medicine*, 37, 374-377.
- Campbell-Yesufu, O. T. and Gandhi, R. T. (2011). Update on human immunodeficiency virus (HIV)-2 infection. *Clinical Infectious Diseases*, 52, 780-787.
- Campoy, S. and Adrio, J. L. (2017). Antifungals. *Biochemical Pharmacology*, 133, 86-96.

- Cardillo, B., Gennaro, A., Merlini, L., Nasini, G. and Servi, S. (1973). New chromenochalcones from *flemingia*. *Phytochemistry*, 12, 2027-2031.
- Carey, F. A. and Giuliano, R. M. (2011). *Organic chemistry*. (8th ed.) New York: McGraw-Hill Companies, Inc.
- Carey, F. A. and Sundberg, R. J. (2000). *Advanced organic chemistry: Part a: structure and mechanisms*. (4th ed.) New York: Kluwer Academic/Plenum publishers.
- Carr, A. and Cooper, D. A. (2000). Adverse effects of antiretroviral therapy. *The Lancet*, 356, 1423-1430.
- Casano, G., Dumètre, A., Pannecouque, C., Hutter, S., Azas, N. and Robin, M. (2010). Anti-HIV and antiplasmodial activity of original flavonoid derivatives. *Bioorganic and Medicinal Chemistry*, 18, 6012-6023.
- Cazarolli, L. H., Kappel, V. D., Zanatta, A. P., Suzuki, D. O. H., Yunes, R. A., Nunes, R. J., Pizzolatti, M. G. and Silva, F. t. R. M. B. (2013). Natural and synthetic chalcones: Tools for the study of targets of action insulin secretagogue or insulin mimetic. In: Atta-ur-Rahman (ed.) *Studies in natural products chemistry*. (1st ed.), (pp.48-83). Netherlands: Elsevier.
- Chandak, B., Sarpate, R., Chatterjee, N. and Baheti, K. (2010). Synthesis, spectral studies and biological activity of some 1,5-benzodiazepine derivatives. *Research Journal of Pharmacy and Technology*, 3, 938-941.
- Chander, S., Ashok, P., Zheng, Y.-T., Wang, P., Raja, K. S., Taneja, A. and Murugesan, S. (2016). Design, synthesis and *in-vitro* evaluation of novel tetrahydroquinoline carbamates as HIV-1 RT inhibitor and their antifungal activity. *Bioorganic Chemistry*, 64, 66-73.

- Chander, S., Penta, A. and Murugesan, S. (2015). Structure-based virtual screening and docking studies for the identification of novel inhibitors against wild and drug resistance strains of HIV-1 RT. *Medicinal Chemistry Research*, 24, 1869-1883.
- Chatterjee, N. R., Chandak, B. G., Thube, S. S., Kulkarnia, S. D. and Deshpande, A. D. (2009). An ultrasonically assisted solvent-free synthesis of some 1, 5-benzodiazepine derivatives possessing significant anti-anxiety action using silica gel as a catalyst. *International Journal of Chemical Sciences*, 7, 805-813.
- Cheenpracha, S., Karalai, C., Ponglimanont, C., Subhadhirasakul, S. and Tewtrakul, S. (2006). Anti-HIV-1 protease activity of compounds from *boesenbergia pandurata*. *Bioorganic and Medicinal Chemistry*, 14, 1710-1714.
- Chen, G.-F., Jia, H.-M., Zhang, L.-Y., Chen, B.-H. and Li, J.-T. (2013a). An efficient synthesis of 2-substituted benzothiazoles in the presence of FeCl₃/montmorillonite k-10 under ultrasound irradiation. *Ultrasonics Sonochemistry*, 20, 627-632.
- Chen, Y.-H., Wang, W.-H., Wang, Y.-H., Lin, Z.-Y., Wen, C.-C. and Chern, C.-Y. (2013b). Evaluation of the anti-inflammatory effect of chalcone and chalcone analogues in a zebrafish model. *Molecules*, 18, 2052-2060.
- Chen, Y., Le, V., Xu, X., Shao, X., Liu, J. and Li, Z. (2014). Discovery of novel 1,5-benzodiazepine-2,4-dione derivatives as potential anticancer agents. *Bioorganic and Medicinal Chemistry Letters*, 24, 3948-3951.
- Chesney, M. A., Morin, M. and Sherr, L. (2000). Adherence to HIV combination therapy. *Social Science and Medicine*, 50, 1599-1605.

- Chimirri, A., Grasso, S., Ottanà, R., Romeo, G. and Zappalà, M. (1990). Synthesis and stereochemistry of novel [1,2,4] oxadiazolo [4,5-a][1,5] benzodiazepine derivatives. *Journal of Heterocyclic Chemistry*, 27, 371-374.
- Chung, M.-I., Weng, J.-R., Lai, M.-H., Yen, M.-H. and Lin, C.-N. (1999). A new chalcone, xanthenes, and a xanthonolignoid from *hypericum geminiflorum*. *Journal of Natural Products*, 62, 1033-1035.
- Cihlar, T. and Fordyce, M. (2016). Current status and prospects of HIV treatment. *Current Opinion in Virology*, 18, 50-56.
- Clayden, J., Greeves, N. and Warren, S. G. (2012). *Organic chemistry*. (2nd ed.) New York: Oxford University Press.
- Cohen, V. I., Jin, B. and Reba, R. C. (1993). The synthesis of substituted 1,5-benzodiazepines. *Journal of Heterocyclic Chemistry*, 30, 835-837.
- Cong, Y., Li, Y., Jin, K., Zhong, S., Zhang, J. Z., Li, H. and Duan, L. (2018). Exploring the reasons for decrease in binding affinity of HIV-2 against HIV-1 protease complex using interaction entropy under polarized force field. *Frontiers in Chemistry*, 6, 1-18.
- Cui, C. M., Li, X. M., Li, C. S., Sun, H. F., Gao, S. S. and Wang, B. G. (2009). Benzodiazepine alkaloids from marine-derived endophytic fungus *aspergillus ochraceus*. *Helvetica Chimica Acta*, 92, 1366-1370.
- Cunico, W., Cechinel, C. A., Bonacorso, H. G., Martins, M. A. P., Zanatta, N., de Souza, M. V. N., Freitas, I. O., Soares, R. P. P. and Krettli, A. U. (2006). Antimalarial activity of 4-(5-trifluoromethyl-1h-pyrazol-1-yl)-chloroquine analogues. *Bioorganic and Medicinal Chemistry Letters*, 16, 649-653.

- Curini, M., Epifano, F., Marcotullio, M. C. and Rosati, O. (2001). Ytterbium triflate promoted synthesis of 1,5-benzodiazepine derivatives. *Tetrahedron letters*, 42, 3193-3195.
- D'arc, M., Ayouba, A., Esteban, A., Learn, G. H., Boué, V., Liegeois, F., Etienne, L., Tagg, N., Leendertz, F. H. and Boesch, C. (2015). Origin of the HIV-1 group O epidemic in western lowland gorillas. *Proceedings of the National Academy of Sciences*, 112, E1343-1352.
- Da Silva, Z. J., Oliveira, I., Andersen, A., Dias, F., Rodrigues, A., Holmgren, B., Andersson, S. and Aaby, P. (2008). Changes in prevalence and incidence of HIV-1, HIV-2 and dual infections in urban areas of Bissau, Guinea-Bissau: Is HIV-2 disappearing? *Aids*, 22, 1195-1202.
- Dabholkar, V. V. and Ansari, F. Y. (2009). Synthesis and characterization of selected fused isoxazole and pyrazole derivatives and their antimicrobial activity. *Journal of the Serbian Chemical Society*, 74, 1219-1228.
- Dannhardt, G., Kiefer, W., Krämer, G., Maehrlein, S., Nowe, U. and Fiebich, B. (2000). The pyrrole moiety as a template for COX-1/COX-2 inhibitors. *European Journal of Medicinal Chemistry*, 35, 499-510.
- Das, K. and Arnold, E. (2013). Hiv-1 reverse transcriptase and antiviral drug resistance. Part 1. *Current Opinion in Virology*, 3, 111-118.
- Das, N., Dash, B., Dhanawat, M. and Shrivastava, S. (2012). Design, synthesis, preliminary pharmacological evaluation, and docking studies of pyrazoline derivatives. *Chemical Papers*, 66, 67-74.
- De Béthune, M.-P. (2010). Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: A review of the last 20 years (1989–2009). *Antiviral Research*, 85, 75-90.

- De Clercq, E. (2009). Anti-hiv drugs: 25 compounds approved within 25 years after the discovery of hiv. *International Journal of Antimicrobial Agents*, 33, 307-320.
- De Clercq, E. (2010). Antiretroviral drugs. *Current Opinion in Pharmacology*, 10, 507-515.
- De Mello, T. F., Bitencourt, H. R., Pedroso, R. B., Aristides, S. M., Lonardon, M. V. and Silveira, T. G. (2014). Leishmanicidal activity of synthetic chalcones in *leishmania (viannia) braziliensis*. *Experimental parasitology*, 136, 27-34.
- De Silva, T. I., Cotten, M. and Rowland-Jones, S. L. (2008). HIV-2: The forgotten AIDS virus. *Trends in Microbiology*, 16, 588-595.
- De, S. K. and Gibbs, R. A. (2005). Scandium (iii) triflate as an efficient and reusable catalyst for synthesis of 1,5-benzodiazepine derivatives. *Tetrahedron Letters*, 46, 1811-1813.
- Deng, H., Yu, Z. Y., Shi, G. Y., Chen, M. J., Tao, K. and Hou, T. P. (2012). Synthesis and *in vitro* antifungal evaluation of 1,3,5-trisubstituted-2-pyrazoline derivatives. *Chemical Biology and Drug Design*, 79, 279-289.
- Dev, S. and Dhaneshwar, S. (2013). A solvent-free protocol for the green synthesis of heterocyclic chalcones. *Der Pharmacia Lettre*, 5, 219-223.
- Di Braccio, M., Grossi, G., Ceruti, M., Rocco, F., Loddo, R., Sanna, G., Busonera, B., Murreddu, M. and Marongiu, M. E. (2005). 1,5-Benzodiazepines XIV. Synthesis of new substituted 9H-bis-[1, 2,4] triazolo [4, 3-a: 3', 4'-d][1,5] benzodiazepines and relate compounds endowed with *in vitro* cytotoxic properties. *Il Farmaco*, 60, 113-125.

- Di Braccio, M., Grossi, G., Roma, G., Vargiu, L., Mura, M. and Marongiu, M. E. (2001). 1,5-Benzodiazepines. Part xii. Synthesis and biological evaluation of tricyclic and tetracyclic 1,5-benzodiazepine derivatives as nevirapine analogues. *European Journal of Medicinal Chemistry*, 36, 935-949.
- Doan, T. N. and Tran, D. T. (2011). Synthesis, antioxidant and antimicrobial activities of a novel series of chalcones, pyrazolic chalcones, and allylic chalcones. *Pharmacology and Pharmacy*, 2, 282.
- Dos Santos, E. F., Cury, N. M., Nascimento, T. A. d., Raminelli, C., Casagrande, G. A., Pereira, C. M., Simionatto, E., Yunes, J. A. and Pizzuti, L. (2017). Ultrasound-promoted synthesis of 3-(thiophen-2-yl)-4,5-dihydro-1*H*-pyrazole-1-carboximidamides and anticancer activity evaluation in leukemia cell lines. *Journal of the Brazilian Chemical Society*, 28, 217-224.
- Duthel, J., Constant, H., Vallon, J., Rochet, T. and Miachon, S. (1992). Quantitation by gas chromatography with selected-ion monitoring mass spectrometry of “natural” diazepam, *N*-desmethyldiazepam and oxazepam in normal human serum. *Journal of Chromatography B: Biomedical Sciences and Applications*, 579, 85-91.
- Eberle, J. and Knopf, C. W. (1996). Nonisotopic assays of viral polymerases and related proteins. In: Kuo, L. C., Olsen, D. B. and Carroll, S. S. (eds.) *Methods in Enzymology*.(pp.257-276). San Diego, USA: Academic press ,Inc.
- Eddarir, S., Cotelle, N., Bakkour, Y. and Rolando, C. (2003). An efficient synthesis of chalcones based on the suzuki reaction. *Tetrahedron Letters*, 44, 5359-5363.
- El-Snyed, A., Abdel-Ghany, H. and El-Snghier, A. (1999). A novel synthesis of pyrano (2, 3-c)-, 1, 3-oxazino (2, 3- b)-, 1,2,4-triazolo (3, 4-b)-, oxazolo (2, 3-b)-, furano (3, 2-c), and 3-substituted-(1,5) benzodiazepin-2-ones. *Synthetic Communications*, 29, 3561-3572.

- ElSohly, H., Joshi, A., Nimrod, A., Walker, L. and Clark, A. (2001). Antifungal chalcones from *Maclura tinctoria*. *Planta Medica*, 67, 87-89.
- Evranos-Aksöz, B., Onurdağ, F. K. and Özgacar, S. Ö. (2015). Antibacterial, antifungal and antimycobacterial activities of some pyrazoline, hydrazone and chalcone derivatives. *Zeitschrift für Naturforschung C, Journal of Biosciences*, 70, 183-189.
- Ezhilarasi, M. R. and Prabha, B. (2015). Comparative study of synthesis and spectral studies of thiophenyl carboxylate derivatives by microwave irradiation and conventional method. *Chemical Science Transactions*, 4, 967-974.
- Fader, L. D., Bethell, R., Bonneau, P., Bös, M., Bousquet, Y., Cordingley, M. G., Coulombe, R., Deroy, P., Faucher, A.-M. and Gagnon, A. (2011). Discovery of a 1,5-dihydrobenzo [b][1,4] diazepine-2,4-dione series of inhibitors of HIV-1 capsid assembly. *Bioorganic and Medicinal Chemistry Letters*, 21, 398-404.
- Faria, N. R., Hodges-Mameletzis, I., Silva, J. C., Rodés, B., Erasmus, S., Paolucci, S., Ruelle, J., Pieniazek, D., Taveira, N. and Treviño, A. (2012). Phylogeographical footprint of colonial history in the global dispersal of human immunodeficiency virus type 2 group a. *Journal of General Virology*, 93, 889-899.
- Flexner, C. (2007). HIV drug development: The next 25 years. *Nature Reviews Drug Discovery*, 6, 959.
- Forsman, A. and Weiss, R. A. (2008). Why is HIV a pathogen? *Trends in Microbiology*, 16, 555-560.
- Frölich, S., Schubert, C., Bienzle, U. and Jenett-Siems, K. (2005). *In vitro* antiplasmodial activity of prenylated chalcone derivatives of hops (*Humulus*

lupulus) and their interaction with haemin. *Journal of Antimicrobial Chemotherapy*, 55, 883-887.

Furniss, B. S., Hannaford, A. J., Smith, P. W. G. and Tatchell, A. R. (1989). *Vogel's textbook of practical organic chemistry*, (5th ed.) England: Longman Scientific and Technical.

Gallo, R. and Salahuddin, S. (1984). Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. *Science*, 224, 497-500.

Goetz, M., Lopez, M., Monaghan, R., Chang, R., Lotti, V. and Chen, T. (1985). Asperlicin, a novel non-peptidal cholecystinin antagonist from *aspergillus alliaceus*. *The Journal of Antibiotics*, 38, 1633-1637.

Gok, S., Demet, M. M., Özdemir, A. and Turan-Zitouni, G. (2010). Evaluation of antidepressant-like effect of 2-pyrazoline derivatives. *Medicinal Chemistry Research*, 19, 94-101.

Gökhan-Kelekçi, N., Yabanoğlu, S., Küpeli, E., Salgın, U., Özgen, Ö., Uçar, G., Yeşilada, E., Kendi, E., Yeşilada, A. and Bilgin, A. A. (2007). A new therapeutic approach in alzheimer disease: Some novel pyrazole derivatives as dual MAO-B inhibitors and antiinflammatory analgesics. *Bioorganic and Medicinal Chemistry*, 15, 5775-5786.

Gomha, S. M., Farghaly, T. A., Mabkhot, Y. N., Zayed, M. E. and Mohamed, A. M. (2017). Microwave-assisted synthesis of some novel azoles and azolopyrimidines as antimicrobial agents. *Molecules*, 22, 346.

Goto, Y., Hayashi, A., Kimura, Y. and Nakayama, M. (1991). Second harmonic generation and crystal growth of substituted thienyl chalcone. *Journal of Crystal Growth*, 108, 688-698.

- Götte, M., Li, X. and Wainberg, M. A. (1999). Hiv-1 reverse transcription: A brief overview focused on structure–function relationships among molecules involved in initiation of the reaction. *Archives of Biochemistry and Biophysics*, 365, 199-210.
- Govindachari, T. and Parthasarathy, P. (1972). Cryptocaryone, a novel 5',6'-dihydrochalcone, from *Cryptocarya bourdilloni* GAMB. *Tetrahedron Letters*, 13, 3419-3420.
- Govindachari, T., Parthasarathy, P., Desai, H. and Shanbhag, M. (1973). Structure of cryptocaryone: A constituent of *Cryptocarya bourdilloni* GAMB. *Tetrahedron*, 29, 3091-3094.
- Greene, W. C. (2007). A history of AIDS: Looking back to see ahead. *European Journal of Immunology*, 37, S94-S102.
- Grossi, G., Di Braccio, M., Roma, G., Ballabeni, V., Tognolini, M., Calcina, F. and Barocelli, E. (2002). 1, 5-Benzodiazepines: Part xiii. Substituted 4*H*-[1, 2, 4] triazolo [4, 3-*a*][1,5] benzodiazepin-5-amines and 4*H*-imidazo [1,2-*a*][1,5] benzodiazepin-5-amines as analgesic, anti-inflammatory and/or antipyretic agents with low acute toxicity. *European Journal of Medicinal Chemistry*, 37, 933-944.
- Guzmán-Gutiérrez, S. L., Nieto-Camacho, A., Castillo-Arellano, J. I., Huerta-Salazar, E., Hernández-Pasteur, G., Silva-Miranda, M., Argüello-Nájera, O., Sepúlveda-Robles, O., Espitia, C. I. and Reyes-Chilpa, R. (2018). Mexican propolis: A source of antioxidants and anti-inflammatory compounds, and isolation of a novel chalcone and γ -caprolactone derivative. *Molecules*, 23, 1-16.
- Hadda, T. B., Genc, Z. K., Masand, V. H., Nebbache, N., Warad, I., Jodeh, S., Genc, M., Mabkhot, Y. N., Barakat, A. and Zamora, H. S. (2015). Computational POM and DFT evaluation of experimental *in-vitro* cancer inhibition of

staurosporine-ruthenium (ii) complexes: The power force of organometallics in drug design. *Acta Chimica Slovenica*, 62, 679-688.

Hargrave, K. D., Proudfoot, J. R., Grozinger, K. G., Cullen, E., Kapadia, S. R., Patel, U. R., Fuchs, V. U., Mauldin, S. C., Vitous, J. and Behnke, M. L. (1991). Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo-and dipyridodiazepinones. *Journal of Medicinal Chemistry*, 34, 2231-2241.

Hartough, H. D. and Conley, L. G. (1947). Acylation studies in the thiophene and furan series. V. Thiophene carboxylic acids and semicarbazones derived from acetylthiophenes. *Journal of the American Chemical Society*, 69, 3096-3098.

Hasan, M., F. M., Alvarez, M. C. G., Yunus, U., Rashid, N and Maqbool, Z. (1990). Reaction of some unsaturated carboxylic-acids with ortho-phenylenediamine in acid medium-ii. *Journal of the Chemical Society of Pakistan* 12, 80-83.

Hassan, S. Y. (2013). Synthesis, antibacterial and antifungal activity of some new pyrazoline and pyrazole derivatives. *Molecules*, 18, 2683-2711.

Hawkins, T. (2006). Appearance-related side effects of HIV-1 treatment. *AIDS Patient Care and STDs*, 20, 6-18.

Hazarika, P., Gogoi, P. and Konwar, D. (2007). Efficient and green method for the synthesis of 1,5-benzodiazepine and quinoxaline derivatives in water. *Synthetic Communications*, 37, 3447-3454.

Hegedüs, A., Hell, Z. and Potor, A. (2005). A simple environmentally-friendly method for the selective synthesis of 1,5-benzodiazepine derivatives using zeolite catalyst. *Catalysis letters*, 105, 229-232.

Heinisch, G., Huber, E., Matuszczak, B., Maurer, A. and Prillinger, U. (1997). Synthesis of pyridazino [3,4-b][1,5] benzodiazepin-5-ones and their

- biological evaluation as non-nucleoside HIV reverse transcriptase inhibitors. *Archiv der Pharmazie - Pharmaceutical and Medicinal Chemistry* 330, 29-34.
- Hemelaar, J. (2013). Implications of HIV diversity for the HIV-1 pandemic. *Journal of Infection*, 66, 391-400.
- Holla, B. S., Mahalinga, M., Poojary, B., Ashok, M. and Akberali, P. (2006). Synthesis of pyrazolines promoted by amberlyst-15 catalyst. *Indian Journal of Chemistry*, 45B, 568-571.
- Hønge, B. L., Jespersen, S., Medina, C., Té, D., Da Silva, Z. J., Christiansen, M., Kjerulff, B., Laursen, A. L., Wejse, C. and Krarup, H. (2018). The challenge of discriminating between HIV-1, HIV-2 and HIV-1/2 dual infections. *HIV Medicine*. 19, 403-410.
- Hopkins, A. L., Mason, J. S. and Overington, J. P. (2006). Can we rationally design promiscuous drugs? *Current Opinion in Structural Biology*, 16, 127-136.
- Huang, Y., Liao, P., Zhang, Y. and Wang, Y. (1997). A facile reduction procedure for nitroarenes with Cp_2TiCl_2/Sm system. *Synthetic Communications*, 27, 1059-1063.
- Hussain, M. M. M., Bhat, K. I., Revanasiddappa, B., Siddiq, A., B and harathi, D. (2011). Antimicrobial and cytotoxic evaluation of (*E*)-thienyl chalcones derived from thiophene-2-carbaldehyde. *Pharmacologyonline*, 3, 880-888.
- Hwang, K.-J., Kim, H.-S., Han, I.-C. and Kim, B.-T. (2012). Synthesis of heterocyclic chalcone derivatives and their radical scavenging ability toward 2, 2-diphenyl-1-picrylhydrazyl (DPPH) free radicals. *Bulletin of the Korean Chemical Society*, 33, 2585-2591.

- Ilango, S., Remya, P. and Ponnuswamy, S. (2013). Synthesis and antimicrobial activity of novel 1,5-benzodiazepines. *Indian Journal of Chemistry*, 52B, 136-140.
- Jadhav, S. B. (2011). Synthesis and antimicrobial study of some novel 2,4-disubstituted 1,5-benzodiazepine derivatives. *International Journal of Pharmacy and Pharmaceutical Sciences*, 3, 181-4.
- Jainey, P. and Bhat, I. (2012). Antitumor, analgesic, and anti-inflammatory activities of synthesized pyrazolines. *Journal of Young Pharmacists*, 4, 82-87.
- Janciene, R., Vektariene, A., Mikulskiene, G., Javorskis, T., Vektaris, G. and Klimavicius, A. (2013). A combined experimental and theoretical study of the synthesis of quinazolino [3, 2-a][1,5] benzodiazepin-13-ones. *Arkivoc*, 4, 57-75.
- Jayapal, M., Prasad, K. S. and Sreedhar, N. (2010). Synthesis and characterization of 2, 5-dihydroxy substituted chalcones using $\text{SOCl}_2/\text{EtOH}$. *International Journal of Pharmacy and Pharmaceutical Sciences*, 1, 361-366.
- Jayapal, M. and Sreedhar, N. (2010). Anhydrous K_2CO_3 as catalyst for the synthesis of chalcones under microwave irradiation. *Journal of Pharmaceutical Sciences and Research*, 2, 644-647.
- Jin, H., Geng, Y., Yu, Z., Tao, K. and Hou, T. (2009). Lead optimization and anti-plant pathogenic fungi activities of daphneolone analogues from *stellera chamaejasme l.* *Pesticide biochemistry and physiology*, 93, 133-137.
- Jois, V. H., Kalluraya, B. and Girisha, K. S. (2014). Synthesis and antioxidant activity study of pyrazoline carrying arylfuran/thiophene moiety. *Journal of the Serbian Chemical Society*, 79, 1469-1475.
- Juvale, K., Pape, V. F. and Wiese, M. (2012). Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein. *Bioorganic and Medicinal Chemistry*, 20, 346-355.

- Kalirajan, R., Sivakumar, S., Jubie, S., Gowramma, B. and Suresh, B. (2009). Synthesis and biological evaluation of some heterocyclic derivatives of chalcones. *International Journal of ChemTech Research*, 1, 27-34.
- Kang, W.-J., Li, D.-H., Han, T., Sun, L., Fu, Y.-B., Sai, C.-M., Li, Z.-L. and Hua, H.-M. (2016). New chalcone and pterocarpoid derivatives from the roots of *flemingia philippinensis* with antiproliferative activity and apoptosis-inducing property. *Fitoterapia*, 112, 222-228.
- Kapoor, K. K., Ganai, B. A., Kumar, S. and Andotra, C. S. (2006). $\text{KHSO}_4 \cdot \text{H}_2\text{O}/\text{SiO}_2$ -catalyzed, one-pot, solvent-free synthesis of pyrazolines, tetrahydrocarbozoles and indoles using microwave irradiation. *Synthetic Communications*, 36, 2727-2735.
- Karabacak, M., Altıntop, M. D., İbrahim Çiftçi, H., Koga, R., Otsuka, M., Fujita, M. and Özdemir, A. (2015). Synthesis and evaluation of new pyrazoline derivatives as potential anticancer agents. *Molecules*, 20, 19066-19084.
- Karki, R., Thapa, P., Kwon, Y.-J. and Lee, E.-S. (2010). Synthesis, topoisomerase i and ii inhibitory activities, and cytotoxicity of 4,6-diaryl-2,4'-bipyridine derivatives. *Bulletin of the Korean Chemical Society*, 31, 1747-1750.
- Kathiravan, M. K., Salake, A. B., Chothe, A. S., Dudhe, P. B., Watode, R. P., Mukta, M. S. and Gadhwe, S. (2012). The biology and chemistry of antifungal agents: A review. *Bioorganic and Medicinal Chemistry*, 20, 5678-5698.
- Katritzky, A. R., Ramsden, C. A., Joule, J. A. and Zhdankin, V. V. (2010). *Handbook of heterocyclic chemistry*. (3rd ed.) Netherlands: Elsevier.
- Kaur, N. and Kishore, D. (2013). Application of chalcones in heterocycles synthesis: Synthesis of 2-(isoxazolo, pyrazolo and pyrimido) substituted analogues of 1,4-benzodiazepin-5-carboxamides linked through an oxyphenyl bridge. *Journal of Chemical Sciences*, 125, 555-560.

- Kavali, J. R. and Badami, B. V. (2000). 1,5-benzodiazepine derivatives of 3-arylsydnonones: Synthesis and antimicrobial activity of 3-aryl-4-[2'-aryl-2',4',6',7'-tetrahydro-(1'H)-1',5'-benzodiazepine-4'-yl]sydnonones. *Il Farmaco*, 55, 406-409.
- Kavvadias, D., Abou-Mandour, A. A., Czygan, F.-C., Beckmann, H., Sand, P., Riederer, P. and Schreier, P. (2000). Identification of benzodiazepines in *artemisia dracuncululus* and *solanum tuberosum* rationalizing their endogenous formation in plant tissue. *Biochemical and Biophysical Research Communications*, 269, 290-295.
- Kayser, O. and Kiderlen, A. F. (2001). *In vitro* leishmanicidal activity of naturally occurring chalcones. *Phytotherapy Research*, 15, 148-152.
- Keele, B. F., Van Heuverswyn, F., Li, Y., Bailes, E., Takehisa, J., Santiago, M. L., Bibollet-Ruche, F., Chen, Y., Wain, L. V. and Liegeois, F. (2006). Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. *Science*, 313, 523-526.
- Kendre, M. M. and Baseer, M. A. (2013). Synthesis and evaluation of some new 3-(2'-hydroxy-phenyl)-5-(4'-substituted-phenyl)-2-pyrazoline-n1-carboxaldehydes as antimicrobial agents. *American Journal of Advanced Drug Delivery*, 1, 387-393.
- Khalil, N. A., Ahmed, E. M., El-Nassan, H. B., Ahmed, O. K. and Al-Abd, A. M. (2012). Synthesis and biological evaluation of novel pyrazoline derivatives as anti-inflammatory and antioxidant agents. *Archives of Pharmacal Research*, 35, 995-1002.
- Khan, S. A. and Asiri, A. M. (2017). Green synthesis, characterization and biological evaluation of novel chalcones as anti bacterial agents. *Arabian Journal of Chemistry*, 10, S2890-S2895.

- Khan, S. A., Asiri, A. M., Kumar, S. and Sharma, K. (2014). Green synthesis, antibacterial activity and computational study of pyrazoline and pyrimidine derivatives from 3-(3,4-dimethoxy-phenyl-1-(2,5-dimethyl-thiophen-3-yl)-propenone. *European Journal of Chemistry*, 5, 85-90.
- Kharatmol, M. G. and Jagdale, D. M. (2017). Eco-friendly synthesis of pyrazoline derivatives. *International Journal of Pharmaceutical and Clinical Research*, 9, 302-308.
- Kitawat, B. S. and Singh, M. (2014). Synthesis, characterization, antibacterial, antioxidant, DNA binding and SAR study of a novel pyrazine moiety bearing 2-pyrazoline derivatives. *New Journal of Chemistry*, 38, 4290-4299.
- Klotz, U. (1990). "Natural" benzodiazepines in man. *The Lancet*, 335, 922.
- Klotz, U. (1991). Occurrence of "natural" benzodiazepines. *Life sciences*, 48, 209-215.
- Koçyiğit-Kaymakçioğlu, B., Beyhan, N., Tabanca, N., Ali, A., Wedge, D. E., Duke, S. O., Bernier, U. R. and Khan, I. A. (2015). Discovery and structure activity relationships of 2-pyrazolines derived from chalcones from a pest management perspective. *Medicinal Chemistry Research*, 24, 3632-3644.
- Konda, S. G., Shaikh, B. M., Chavan, S. A. and Dawane, B. S. (2011). Polyethylene glycol (PEG-400): An efficient and recyclable reaction medium for the synthesis of novel 1-5-benzodiazepines and their antimicrobial activity. *Chinese Chemical Letters*, 22, 65-68.
- Koohmareh, G. A., Mirkhani, V., Fallah, H. R. and Sajadi, S. M. S. (2015). Synthesis, characterization, and optical properties of new pyridine- and thiophene-based copolymer bearing bulky naphthyl group. *Polymer Bulletin*, 72, 2979-2990.

- Koran, K., Özen, F., Biryani, F., Demirelli, K. and Görgülü, A. O. (2016). Eu⁺³ - doped chalcone substituted cyclotriphosphazenes: Synthesis, characterizations, thermal and dielectrical properties. *Inorganica Chimica Acta*, 450, 162-169.
- Kostanecki, S. V. and Tambor, J. (1899). Ueber die sechs isomeren monooxybenzalacetophenone (monooxychalkone). *Berichte der Deutschen Chemischen Gesellschaft*, 32, 1921-1926.
- Krezel, I. and Graczyk, J. (1998). Synthesis and preliminary antileukemic studies of cyclic mitoguanone analogues. *Il Farmaco*, 53, 244-247.
- Krishna, B. and Chaganty, R. (1973). Cardamonin and alpinetin from the seeds of *alpinia speciosa*. *Phytochemistry*, 12, 238.
- Kulkarni, R. R., Tupe, S. G., Gample, S. P., Chandgude, M. G., Sarkar, D., Deshpande, M. V. and Joshi, S. P. (2014). Antifungal dimeric chalcone derivative kamalachalcone E from *Mallotus philippinensis*. *Natural Product Research*, 28, 245-250.
- Kumar, C., Loh, W.-S., Ooi, C. W., Quah, C. K. and Fun, H.-K. (2013a). Heteroaryl chalcones: Design, synthesis, X-ray crystal structures and biological evaluation. *Molecules*, 18, 12707-12724.
- Kumar, C., Loh, W.-S., Ooi, C. W., Quah, C. K. and Fun, H.-K. (2013b). Structural correlation of some heterocyclic chalcone analogues and evaluation of their antioxidant potential. *Molecules*, 18, 11996-12011.
- Kumar, H., Saini, D., Jain, S. and Jain, N. (2013c). Pyrazole scaffold: A remarkable tool in the development of anticancer agents. *European Journal of Medicinal Chemistry*, 70, 248-258.

- Kumar, R., Chaudhary, P., Nimesh, S., Verma, A. K. and Chandra, R. (2006). An efficient synthesis of 1,5-benzodiazepine derivatives catalyzed by silver nitrate. *Green Chemistry*, 8, 519-521.
- Kumar, R. and Joshi, Y. (2007). Synthesis, spectral studies and biological activity of 3H-1,5-benzodiazepine derivatives. *Arkivoc*, 13, 142-149.
- Kumar, R. and Joshi, Y. (2008). Synthesis and antimicrobial, antifungal and anthelmintic activities of 3H-1,5-benzodiazepine derivatives. *Journal of the Serbian Chemical Society*, 73, 937-943.
- Kumar, V., Kaur, K., Gupta, G. K. and Sharma, A. K. (2013d). Pyrazole containing natural products: Synthetic preview and biological significance. *European Journal of Medicinal Chemistry*, 69, 735-753.
- Kumaraswamy, M., Vaidya, V., Chandrashekhar, C., Mathias, D. P., Shivakumar, H. and Mahadevan, K. (2013). Synthesis of novel 2,5-dihydro-1H-1, 5-benzodiazepines encompassing naphtho[2,1-b] furan and evaluation of their pharmacological activities. *International Journal of Pharmaceutical, Chemical and Biological Sciences*, 3, 281-7.
- Kuo, C.-W., Wang, C.-C., Kavala, V. and Yao, C.-F. (2008). Efficient TCT-catalyzed synthesis of 1,5-benzodiazepine derivatives under mild conditions. *Molecules*, 13, 2313-2325.
- Larru, B., Eby, J. and Lowenthal, E. D. (2014). Antiretroviral treatment in HIV-1 infected pediatric patients: Focus on efavirenz. *Pediatric Health, Medicine and Therapeutics*, 5, 29-42.
- Lévai, A. (1997). Synthesis of pyrazolines by the reactions of α , β -enones with diazomethane and hydrazines. *Chemistry of Heterocyclic Compounds*, 33, 647-659.

- Lewthwaite, P. and Melhuish, A. (2018). Natural history of HIV and AIDS, 46. 356-361, *Medicine*.
- Li, J.-T., Yang, W.-Z., Wang, S.-X., Li, S.-H. and Li, T.-S. (2002). Improved synthesis of chalcones under ultrasound irradiation. *Ultrasonics Sonochemistry*, 9, 237-239.
- Li, J.-T., Zhang, X.-H. and Lin, Z.-P. (2007). An improved synthesis of 1, 3, 5-triaryl-2-pyrazolines in acetic acid aqueous solution under ultrasound irradiation. *Beilstein Journal of Organic Chemistry*, 13, 1-4.
- Lin, Z.-P. and Li, J.-T. (2012). A convenient and efficient protocol for the synthesis of 1, 3, 5-triaryl-2-pyrazolines in acetic acid under ultrasound irradiation. *Journal of Chemistry*, 9, 267-271.
- Liu, J.-J., Sun, J., Fang, Y.-B., Yang, Y.-A., Jiao, R.-H. and Zhu, H.-L. (2014). Synthesis, and antibacterial activity of novel 4, 5-dihydro-1*H*-pyrazole derivatives as DNA gyrase inhibitors. *Organic and Biomolecular Chemistry*, 12, 998-1008.
- Lloyd, D. and Cleghorn, H. P. (1974). 1,5-Benzodiazepines. *In*: Katritzky, A. R. and Boulton, A. J. (eds.) *Advances in heterocyclic chemistry* (17 vol), (pp. 27-41) New York, USA: Academic Press, Inc.
- Lloyd, D. and McNab, H. (1998). 1,5-Benzodiazepines and 1,5-benzodiazepinium salts. *In*: Katritzky, A. R. (ed.) *Advances in heterocyclic chemistry*. (71 vol), (pp. 2-48). San Diego. USA: Academic Press Inc. .
- Loh, W.-S., Quah, C. K., Chia, T. S., Fun, H.-K., Sapnakumari, M., Narayana, B. and Sarojini, B. K. (2013). Synthesis and crystal structures of *N*-substituted pyrazolines. *Molecules*, 18, 2386-2396.

- Lydyard, P. M., Cole, M. F., Holton, J., Irving, W. L., Porakishvili, N., Venkatesan, P. and Ward, K. N. (2010). *Case studies in infectious disease*. (1st ed.) New York and London: Garland Science, Taylor and Francis Group.
- Ma, Y. and Zhang, Y. (2002). Derivatives of 2,3-dihydro-1*H*-1,5-benzodiazepine from *o*-nitroanilines and chalcones induced by low-valent titanium. *Synthetic Communications*, 32, 165-169.
- Maartens, G., Celum, C. and Lewin, S. R. (2014). HIV infection: Epidemiology, pathogenesis, treatment, and prevention. *The Lancet*, 384, 258-271.
- Mabkhot, Y. N., Alatibi, F., El-Sayed, N. N. E., Al-Showiman, S., Kheder, N. A., Wadood, A., Rauf, A., Bawazeer, S. and Hadda, T. B. (2016). Antimicrobial activity of some novel armed thiophene derivatives and petra/osiris/molinspiration (POM) analyses. *Molecules*, 21, 1-16.
- Mabkhot, Y. N., Barakat, A., Yousuf, S., Choudhary, M. I., Frey, W., Hadda, T. B. and Mubarak, M. S. (2014). Substituted thieno [2, 3-*b*] thiophenes and related congeners: Synthesis, β -glucuronidase inhibition activity, crystal structure, and POM analyses. *Bioorganic and Medicinal Chemistry*, 22, 6715-6725.
- Maghsoodlou, M. T., Hassankhani, A., Shaterian, H. R., Habibi-Khorasani, S. M. and Mosaddegh, E. (2007). Zinc oxide as an economical and efficient catalyst for the one-pot preparation of β -acetamido ketones via a four-component condensation reaction. *Tetrahedron Letters*, 48, 1729-1734.
- Mahdi, M., Szojka, Z., Mótyán, J. A. and Tózsér, J. (2018). Inhibitory effects of HIV-2 vpx on replication of HIV-1. *Journal of Virology*, 92, e00554-18.
- Mandge, S., Singh, H. P., Gupta, S. D. and Moorthy, N. (2007). Synthesis and characterization of some chalcone derivatives. *Trends in Applied Sciences Research*, 2, 52-56.

- Mathew, B., Suresh, J., Anbazhagan, S., Paulraj, J. and Krishnan, G. K. (2014). Heteroaryl chalcones: Mini review about their therapeutic voyage. *Biomedicine and Preventive Nutrition*, 4, 451-458.
- Mazimba, O. (2015). Antimicrobial activities of heterocycles derived from thienylchalcones. *Journal of King Saud University-Science*, 27, 42-48.
- Medina, J. H., Peña, C., Piva, M., Paladini, A. C. and De Robertis, E. (1988). Presence of benzodiazepine-like molecules in mammalian brain and milk. *Biochemical and Biophysical Research Communications*, 152, 534-539.
- Menéndez-Arias, L. (2013). Molecular basis of human immunodeficiency virus type 1 drug resistance: Overview and recent developments. *Antiviral Research*, 98, 93-120.
- Menendez-Arias, L. and Álvarez, M. (2014). Antiretroviral therapy and drug resistance in human immunodeficiency virus type 2 infection. *Antiviral Research*, 102, 70-86.
- Monga, V., Goyal, K., Steindel, M., Malhotra, M., Rajani, D. P. and Rajani, S. D. (2014). Synthesis and evaluation of new chalcones, derived pyrazoline and cyclohexenone derivatives as potent antimicrobial, antitubercular and antileishmanial agents. *Medicinal Chemistry Research*, 23, 2019-2032.
- More, P. E., Bandgar, B. P. and Kamble, V. T. (2012). Zinc oxide as a regioselective and heterogeneous catalyst for the synthesis of chalcones at room temperature. *Catalysis Communications*, 27, 30-32.
- Morrison, R. T. and Boyd, R. N. (2002). *Organic chemistry*. (6th ed.) New Delhi: Prentic-Hall of India.

- Murai, K., Nakatani, R., Kita, Y. and Fujioka, H. (2008). One-pot three-component reaction providing 1,5-benzodiazepine derivatives. *Tetrahedron*, 64, 11034-11040.
- Musumarra, G. and Ballistreri, F. P. (1980). Studies of substituent effects by carbon-13 NMR spectroscopy. Thiophene and furan chalcone analogues. *Organic Magnetic Resonance*, 14, 384-391.
- Nabih, K., Baouid, A., Hasnaoui, A. and Kenz, A. (2004). Highly regio- and diastereoselective 1,3-dipolar cycloaddition of nitrile oxides to 2,4-dimethyl-3H-1,5-benzodiazepines: Synthesis of bis [1, 2,4-oxadiazolo][1, 5] benzodiazepine derivatives. *Synthetic Communications*, 34, 3565-3572.
- Nagarajan, G. R. and Parmar, V. S. (1977). Three new flavonoids in prunus cerasus. *Phytochemistry*, 16, 1317-1318.
- Narender, T. and Reddy, K. P. (2007). A simple and highly efficient method for the synthesis of chalcones by using borontrifluoride-etherate. *Tetrahedron Letters*, 48, 3177-3180.
- Nasir Abbas Bukhari, S., Jantan, I. and Jasamai, M. (2013). Anti-inflammatory trends of 1,3-diphenyl-2-propen-1-one derivatives. *Mini Reviews in Medicinal Chemistry*, 13, 87-94.
- Nawrocka, W., Sztuba, B., Opolski, A., Wietrzyk, J., Kowalska, M. W. and Glowiak, T. (2001a). Synthesis and antiproliferative activity *in vitro* of novel 1, 5-benzodiazepines. Part ii. *Archiv der Pharmazie-Pharmaceutical and Medicinal Chemistry*, 334, 3-10.
- Nawrocka, W., Sztuba, B. and Zimecki, M. (2001b). Synthesis and immunotropic properties of 5-substituted 1,5-benzodiazepin-2-ones derivatives in cultures of human peripheral blood cells, part iii. *Archiv der Pharmazie - Pharmaceutical and Medicinal Chemistry*, 334, 11-16.

- Nivoix, Y., Levêque, D., Herbrecht, R., Koffel, J.-C., Beretz, L. and Ubeaud-Sequier, G. (2008). The enzymatic basis of drug-drug interactions with systemic triazole antifungals. *Clinical Pharmacokinetics*, 47, 779-792.
- Nowakowska, Z., Kędzia, B. and Schroeder, G. (2008). Synthesis, physicochemical properties and antimicrobial evaluation of new (*E*)-chalcones. *European Journal of Medicinal Chemistry*, 43, 707-713.
- Ogundeji, A. O., Pohl, C. H. and Sebolai, O. M. (2016). Repurposing of aspirin and ibuprofen as candidate anti-cryptococcus drugs. *Antimicrobial Agents and Chemotherapy*, 60, 4799-4808.
- Oliveira, S., Pizzuti, L., Quina, F., Flores, A., Lund, R., Lencina, C., Pacheco, B. S., de Pereira, C. M. and Piva, E. (2014). Anti-candida, anti-enzyme activity and cytotoxicity of 3,5-diaryl-4,5-dihydro-1*H*-pyrazole-1-carboximidamides. *Molecules*, 19, 5806-5820.
- Özdemir, A. (2013). Synthesis and antimicrobial activity of some pyrazoline derivatives bearing amide moiety. *Marmara Pharmaceutical Journal*, 17, 187-192.
- Özdemir, A., Altıntop, M. D., Kaplancıklı, Z. A., Turan-Zitouni, G., Çiftçi, G. A. and Yıldırım, Ş. U. (2013). Synthesis of 1-acetyl-3-(2-thienyl)-5-aryl-2-pyrazoline derivatives and evaluation of their anticancer activity. *Journal of Enzyme Inhibition and Medicinal Chemistry*, 28, 1221-1227.
- Özdemir, A., Turan-Zitouni, G., Asım Kaplancıklı, Z., Revial, G. and Güven, K. (2007a). Synthesis and antimicrobial activity of 1-(4-aryl-2-thiazolyl)-3-(2-thienyl)-5-aryl-2-pyrazoline derivatives. *European Journal of Medicinal Chemistry*, 42, 403-409.

- Özdemir, A., ZIitouni, G. and Kaplancikli, Z. A. (2008). Novel analogues of 2-pyrazoline: Synthesis, characterization, and antimycobacterial evaluation. *Turkish Journal of Chemistry*, 32, 529-538.
- Ozdemir, Z., Kandilci, H. B., Gumusel, B., Calis, U. and Bilgin, A. A. (2008). Synthesis and studies on antidepressant and anticonvulsant activities of some 3-(2-thienyl) pyrazoline derivatives. *Archiv der Pharmazie Chemistry in Life Science*, 341, 701-707.
- Özdemir, Z., Kandilci, H. B., Gümüsel, B., Çalış, Ü. and Bilgin, A. A. (2007b). Synthesis and studies on antidepressant and anticonvulsant activities of some 3-(2-furyl)-pyrazoline derivatives. *European Journal of Medicinal Chemistry*, 42, 373-379.
- Panigrahi, N., Ganguly, S., Panda, J. and Praharsha, Y. (2014). Ultrasound assisted synthesis and antimicrobial evaluation of novel thiophene chalcone derivatives. *Chemical Science Transactions*, 3, 1163-1171.
- Pasha, M. and Jayashankara, V. (2006a). An expeditious synthesis of 1,5-benzodiazepine derivatives catalyzed by $CdCl_2$. *Indian Journal of Chemistry*, 45B, 2716-2719.
- Pasha, M. A. and Jayashankara, V. P. (2006b). Synthesis of 1,5-benzodiazepine derivatives catalysed by zinc chloride. *Heterocycles*, 68, 1017-1023.
- Patel, N. B., Shaikh, F. M., Patel, H. R. and Rajani, D. (2016). Synthesis of 2-pyrazolines from pyridine based chalcone by conventional and microwave techniques: Their comparison and antimicrobial studies. *Journal of Saudi Chemical Society*, 20, S451-S456.
- Patel, S. and Cassidy, S. R. (2018). Diagnosis and monitoring of hiv (including resistance testing). *Medicine*, 46, 283-286.

- Patel, V. M. and Desai, K. R. (2004). Eco-friendly synthesis of fluorine-containing pyrazoline derivatives over potassium carbonate. *Arkivoc*, 2004, 123-129.
- Pathak, V. N., Joshi, R. and Gupta, N. (2007). Synthesis, spectral studies and antimicrobial activity of 7-chloro-2-alkyl/aryl-4-alkyl/aryl-3-arylidene-3H-1,5-benzodiazepines. *Indian Journal of Chemistry*, 46B, 1191-1197.
- Pathak, V. N., Joshi, R., Sharma, J., Gupta, N. and Rao, V. M. (2009). Mild and ecofriendly tandem synthesis, and spectral and antimicrobial studies of N^1 -acetyl-5-aryl-3-(substituted styryl) pyrazolines. *Phosphorus, Sulfur, and Silicon*, 184, 1854-1865.
- Pedersen, O. S. and Pedersen, E. B. (1999). Non-nucleoside reverse transcriptase inhibitors: The nrti boom. *Antiviral Chemistry and Chemotherapy*, 10, 285-314.
- Pena, C., Medina, J., Piva, M., Diaz, L., Danilowicz, C. and Paladini, A. (1991). Naturally occurring benzodiazepines in human milk. *Biochemical and Biophysical Research Communications*, 175, 1042-1050.
- Petrikkos, G. and Skiada, A. (2007). Recent advances in antifungal chemotherapy. *International Journal of Antimicrobial Agents*, 30, 108-117.
- Ph.B.N, Dat.X.N and Michel.S (1956). Chalcone derivatives of thiophene and their thiosemicarbazones. *Bulletin de la Societe Chimique de France*, 11, 1646-1650.
- Pilmis, B., Puel, A., Lortholary, O. and Lanternier, F. (2016). New clinical phenotypes of fungal infections in special hosts. *Clinical Microbiology and Infection*, 22, 681-687.
- Piva, M. A., Medina, J. H., de Blas, A. L. and Pena, C. (1991). Formation of benzodiazepine-like molecules in rat brain. *Biochemical and Biophysical Research Communications*, 180, 972-981.

- Plantier, J.-C., Leoz, M., Dickerson, J. E., De Oliveira, F., Cordonnier, F., Lemée, V., Damond, F., Robertson, D. L. and Simon, F. (2009). A new human immunodeficiency virus derived from gorillas. *Nature Medicine*, 15, 871-872.
- Portman, M. (2018). HIV Prevention strategies. *Medicine*, 46, 293-299.
- Prabhudeva, M., Renuka, N. and Kumar, K. (2018). Synthesis of thiophene-pyrazole conjugates as potent antimicrobial and radical scavengers. *Current Chemistry Letters*, 7, 73-80.
- Prabhudeva, M. G., Bharath, S., Kumar, A. D., Naveen, S., Lokanath, N. K., Mylarappa, B. N. and Kumar, K. A. (2017). Design and environmentally benign synthesis of novel thiophene appended pyrazole analogues as anti-inflammatory and radical scavenging agents: Crystallographic, in silico modeling, docking and sar characterization. *Bioorganic Chemistry*, 73, 109-120.
- Prajapati, S. P., Kaushik, N. K., Zaveri, M., Mohanakrishanan, D., Kawathekar, N. and Sahal, D. (2012). Synthesis, characterization and antimalarial evaluation of new β -benzoylstyrene derivatives of acridine. *Arabian Journal of Chemistry*, 10, S274–S280.
- Prasad, Y. R., Kumar, P. P., Kumar, P. R. and Rao, A. S. (2008). Synthesis and antimicrobial activity of some new chalcones of 2-acetyl pyridine. *Journal of Chemistry*, 5, 144-148.
- Puodziunaite, B. D., Janciene, R., Kosychova, L. and Stumbreviciute, Z. (2000). On the synthetic way to novel peri-annelated imidazo [1,5] benzodiazepinones as the potent non-nucleoside reverse transcriptase inhibitors. *Arkivoc*, 4, 512-522.

- Rahman, A., Qureshi, R., Kiran, M. and Ansari, F. L. (2007). Electron affinities, solvation energies and redox potentials of some chalcones: Substituents' effect and correlation with semi-empirical MO energies. *Turkish Journal of Chemistry*, 31, 25-34.
- Rai, N. S., Kalluraya, B., Lingappa, B., Shenoy, S. and Puranic, V. G. (2008). Convenient access to 1,3,4-trisubstituted pyrazoles carrying 5-nitrothiophene moiety via 1, 3-dipolar cycloaddition of sydnone with acetylenic ketones and their antimicrobial evaluation. *European Journal of Medicinal Chemistry*, 43, 1715-1720.
- Raj, C. G. D., Sarojini, B. K., Hegde, S., Sreenivasa, S., Ravikumar, Y. S., Bhanuprakash, V., Revanaiah, Y. and Ragavendra, R. (2013). *In vitro* biological activities of new heterocyclic chalcone derivatives. *Medicinal Chemistry Research*, 22, 2079-2087.
- Ramesh, B., Babitha, S. and Prasad, Y. R. (2009). Synthesis and antimicrobial activity of some new 2-pyrazoline derivatives *International Journal of Chemical Science*, 7, 2572-2576.
- Ramesh, B. and Sumana, T. (2010). Synthesis and anti-inflammatory activity of pyrazolines. *Journal of Chemistry*, 7, 514-516.
- Ranganathan, K., Suresh, R., Vanangamudi, G., Thirumurthy, K., Mayavel, P. and Thirunarayanan, G. (2014). SOCl₂ catalyzed cyclization of chalcones: Synthesis and spectral studies of some bio-potent *H^I* pyrazoles. *Bulletin of the Chemical Society of Ethiopia*, 28, 271-288.
- Rani, M. and Mohamad, Y. (2014). Synthesis, studies and *in vitro* antibacterial activity of some 5-(thiophene-2-yl)-phenyl pyrazoline derivatives. *Journal of Saudi Chemical Society*, 18, 411-417.

- Ranjit, P. M., Chowdary, Y. A., Rahaman, S. A., Nagarani, T. and Prasad, Y. R. (2013). Synthesis of piperazine nucleus containing novel chalcones and screening of antimicrobial activity against human pathogens. *Indo American Journal of Pharmaceutical Research*, 3, 4611-18.
- Rao, J. M., Babu, S. S., Subrahmanyam, K. and Rao, K. J. (1978). Homoflemingin and flemiwallichin-C from the leaves of *flemingia wallichii* W. and A. *Current Science*, 47, 584-584.
- Rao, J. M., Subrahmanyam, K. and Rao, K. J. (1975). Flemistrictin-a, a new chalcone from the leaves of *flemingia stricta roxb.(leguminosae)*. *Current Science*, 44, 158-159.
- Reddy, B. M. and Sreekanth, P. M. (2003). An efficient synthesis of 1,5-benzodiazepine derivatives catalyzed by a solid superacid sulfated zirconia. *Tetrahedron Letters*, 44, 4447-4449.
- Reddy, K. S., Reddy, C. V., Mahesh, M., Reddy, K. R., Raju, P. V. and Narayana Reddy, V. (2007). Zirconium (iv) chloride-catalyzed synthesis of 1,5-benzodiazepine derivatives. *Canadian Journal of Chemistry*, 85, 184-188.
- Repanas, A., Katsori, A. and Hadjipavlou-Litina, D. (2013). Chalcones in cancer: understanding their role in terms of QSAR. II part. *Mini Reviews in Medicinal Chemistry*, 13, 952-970.
- Revie, N. M., Iyer, K. R., Robbins, N. and Cowen, L. E. (2018). Antifungal drug resistance: Evolution, mechanisms and impact. *Current Opinion in Microbiology*, 45, 70-76.
- Richman, D., Rosenthal, A., Skoog, M., Eckner, R., Chou, T.-C., Sabo, J. and Merluzzi, V. (1991). BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. *Antimicrobial Agents and Chemotherapy*, 35, 305-308.

- Rizvi, S. U. F., Ahmad, M., Bukhari, M. H., Montero, C., Chatterjee, P., Detorio, M. and Schinazi, R. F. (2014). Anti-HIV-1 screening of (2E)-3-(2-chloro-6-methyl/methoxyquinolin-3-yl)-1-(aryl)prop-2-en-1-ones. *Medicinal Chemistry Research*, 23, 402-407.
- Rizvi, S. U. F., Siddiqui, H. L., Ahmad, M. N., Ahmad, M. and Bukhari, M. H. (2012). Novel quinolyl-thienyl chalcones and their 2-pyrazoline derivatives with diverse substitution pattern as antileishmanial agents against leishmania major. *Medicinal Chemistry Research*, 21, 1322-1333.
- Rizvi, S. U. F., Siddiqui, H. L., Parvez, M., Ahmad, M., Siddiqui, W. A. and Yasinzi, M. M. (2010). Antimicrobial and antileishmanial studies of novel (2E)-3-(2-chloro-6-methyl/methoxyquinolin-3-yl)-1-(aryl) prop-2-en-1-ones. *Chemical and Pharmaceutical Bulletin*, 58, 301-306.
- Roma, G., Grossi, G., Di Braccio, M., Ghia, M. and Mattioli, F. (1991). 1,5-Benzodiazepines IX. A new route to substituted 4h-[1, 2, 4] triazolo [4, 3-a][1,5] benzodiazepin-5-amines with analgesic and/or anti-inflammatory activities. *European Journal of Medicinal Chemistry*, 26, 489-496.
- Roman, G., Comanita, E. and Comanita, B. (2002). Synthesis and reactivity of mannich bases. XIV. Base-catalyzed cyclocondensation of beta-aminoketones to 1,5-benzodiazepines and 1,4-naphthodiazepines. *Acta Chimica Slovenica*, 49, 575-586.
- Rostamizadeh, S., Amani, A. M., Mahdavinia, G. H., Amiri, G. and Sepehrian, H. (2010). Ultrasound promoted rapid and green synthesis of 1,8-dioxo-octahydroxanthenes derivatives using nanosized MCM-41-SO₃H as a nanoreactor, nanocatalyst in aqueous media. *Ultrasonics Sonochemistry*, 17, 306-309.

- Rothenberg, G., Downie, A. P., Raston, C. L. and Scott, J. L. (2001). Understanding solid/solid organic reactions. *Journal of the American Chemical Society*, 123, 8701-8708.
- Rothstein, J. D., Garland, W., Puia, G., Guidotti, A., Weber, R. J. and Costa, E. (1992). Purification and characterization of naturally occurring benzodiazepine receptor ligands in rat and human brain. *Journal of Neurochemistry*, 58, 2102-2115.
- Saitoh, T. and Shibata, S. (1975). New type chalcones from *licorice* root. *Tetrahedron Letters*, 16, 4461-4462.
- Sala, M. and Vartanian, J. (1998). HIV-1 reverse transcriptase: An out-of-the-ordinary enzyme. *Bulletin de l'Institut Pasteur*, 96, 49-63.
- Sand, P., Kavvadias, D., Feineis, D., Riederer, P., Schreier, P., Kleinschnitz, M., Czygan, F.-C., Abou-Mandour, A., Bringmann, G. and Beckmann, H. (2000). Naturally occurring benzodiazepines: Current status of research and clinical implications. *European Archives of Psychiatry and Clinical Neuroscience*, 250, 194-202.
- Sangameswaran, L., Fales, H. M., Friedrich, P. and De Blas, A. L. (1986). Purification of a benzodiazepine from bovine brain and detection of benzodiazepine-like immunoreactivity in human brain. *Proceedings of the National Academy of Sciences*, 83, 9236-9240.
- Sangshetti, J. N., Kokare, N. D. and Shinde, D. B. (2007). Sulfanilic acid catalyzed solvent-free synthesis of 1,5-benzodiazepine derivatives. *Chinese Chemical Letters*, 18, 1305-1308.
- Sarafianos, S. G., Marchand, B., Das, K., Himmel, D. M., Parniak, M. A., Hughes, S. H. and Arnold, E. (2009). Structure and function of HIV-1 reverse

transcriptase: Molecular mechanisms of polymerization and inhibition. *Journal of molecular biology*, 385, 693-713.

Sasikala, R., Thirumurthy, K., Mayavel, P. and Thirunarayanan, G. (2012). Eco-friendly synthesis and antimicrobial activities of some 1-phenyl-3 (5-bromothiophen-2-yl)-5-(substituted phenyl)-2-pyrazolines. *Organic and Medicinal Chemistry Letters*, 2, 20.

Sax, P. E., Cohen, C. J. and Kuritzkes, D. R. (2014). *HIV Essentials*. (7th ed.) Burlington: Jones and Bartlett Learning.

Shah, N., Biradar, A., Habib, S., Dhole, J., Baseer, M. and Kulkarni, P. (2011). Synthesis and antimicrobial studies of some novel pyrazolines. *Der Pharma Chemica*, 3, 167-171.

Sharma, B., Agrawal, S. and Gupta, K. (2008). Colour reactions of chalcones and their mechanism (a review). *Oriental Journal of Chemistry*, 24, 289-294.

Sharma, S., Jain, R. and Chawla, C. (2013). Synthesis and biological activities of some benzodiazepine derivatives. *Journal of Chemical and Pharmaceutical Research*, 5, 46-55.

Sharp, P. M. and Hahn, B. H. (2010). The evolution of HIV-1 and the origin of AIDS. *Philosophical Transactions of the Royal Society of London B: Biological Sciences*, 365, 2487-2494.

Sharp, P. M. and Hahn, B. H. (2011). Origins of HIV and the AIDS pandemic. *Cold Spring Harbor Perspectives in Medicine*, 1, 1-22.

Sharp, P. M., Shaw, G. M. and Hahn, B. H. (2005). Simian immunodeficiency virus infection of chimpanzees. *Journal of Virology*, 79, 3891-3902.

- Shimokoriyama, M. (1957). Anthochlor pigments of *Coreopsis tinctoria*. *Journal of the American Chemical Society*, 79, 214-220.
- Shinde, P. V., Shingate, B. B. and Shingare, M. S. (2011). An organocatalyzed and ultrasound accelerated expeditious synthetic route to 1,5-benzodiazepines under solvent-free conditions. *Bulletin of the Korean Chemical Society*, 32, 1179-1182.
- Shobha, D., Chari, M. A., Mukkanti, K. and Ahn, K. (2009). Silica gel-supported sulfuric acid catalyzed synthesis of 1,5-benzodiazepine derivatives. *Journal of Heterocyclic Chemistry*, 46, 1028-1033.
- Silva, W. A., Andrade, C. K. Z., Napolitano, H. B., Vencato, I., Lariucci, C., Castro, M. and Camargo, A. J. (2013). Biological and structure-activity evaluation of chalcone derivatives against bacteria and fungi. *Journal of the Brazilian Chemical Society*, 24, 133-144.
- Singh, I. P. and Bodiwala, H. S. (2010). Recent advances in anti-HIV natural products. *Natural Product Reports*, 27, 1781-1800.
- Singh, P., Negi, J. S., Nee Pant, G. J., Rawat, M. S. and Budakoti, A. (2009). Synthesis and characterization of a novel 2-pyrazoline. *Molbank*, 2009, M614.
- Sluis-Cremer, N. and Tachedjian, G. (2008). Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors. *Virus Research*, 134, 147-156.
- Smith, S. G., Sanchez, R. and Zhou, M.-M. (2014). Privileged diazepine compounds and their emergence as bromodomain inhibitors. *Chemistry and Biology*, 21, 573-583.

- Solomon, V. R. and Lee, H. (2012). Anti-breast cancer activity of heteroaryl chalcone derivatives. *Biomedicine and Pharmacotherapy*, 66, 213-220.
- Srivastava, Y., Malhotra, G. and Gothwal, P. (2010b). MAOS Protocol for synthesis of some biologically active N¹-cinnamoyl-3,5-diaryl-2-pyrazolines. *Rasayan Journal of Chemistry*, 3, 584-588.
- Subramanian, M., Vanangamudi, G. and Thirunarayanan, G. (2013). Hydroxyapatite catalyzed aldol condensation: Synthesis, spectral linearity, antimicrobial and insect antifeedant activities of some 2,5-dimethyl-3-furyl chalcones. *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy*, 110, 116-123.
- Supuran, C. T., Popescu, A., Ilisiu, M., Costandache, A. and Banciu, M. D. (1996). Carbonic anhydrase inhibitors. Part 36. Inhibition of isozymes I and II with schiff bases derived from chalcones and aromatic/heterocyclic sulfonamides. *European Journal of Medicinal Chemistry*, 31, 439-447.
- Svetaz, L., Tapia, A., López, S. N., Furlán, R. L., Petenatti, E., Pioli, R., Schmeda-Hirschmann, G. and Zacchino, S. A. (2004). Antifungal chalcones and new caffeic acid esters from zuccagnia punctata acting against soybean infecting fungi. *Journal of Agricultural and Food Chemistry*, 52, 3297-3300.
- Syam, S., Abdelwahab, S. I., Al-Mamary, M. A. and Mohan, S. (2012). Synthesis of chalcones with anticancer activities. *Molecules*, 17, 6179-6195.
- Tadigoppula, N., Korthikunta, V., Gupta, S., Kancharla, P., Khaliq, T., Soni, A., Srivastava, R. K., Srivastava, K., Puri, S. K. and Raju, K. S. R. (2012). Synthesis and insight into the structure–activity relationships of chalcones as antimalarial agents. *Journal of Medicinal Chemistry*, 56, 31-45.
- Thirunarayanan, G., Mayavel, P., Thirumurthy, K., Kumar, S. D., Sasikala, R., Nisha, P. and Nithyaranjani, A. (2013). Eco-friendly synthesis and spectral

correlations in some 1-phenyl-3-(5-bromothiophen-2-yl)-5-(substituted phenyl)-2-pyrazolines. *European Chemical Bulletin*, 2, 598-605.

Thirunarayanan, G. and Sekar, K. (2016). Solvent-free one-pot cyclization and acetylation of chalcones: Synthesis of some 1-acetyl pyrazoles and spectral correlations of 1-(3-(3,4-dimethylphenyl)-5-(substituted phenyl)-4,5-dihydro-1H-pyrazole-1-yl) ethanones. *Journal of Saudi Chemical Society*, 20, 661-672.

Tie, Y., Wang, Y. F., Boross, P. I., Chiu, T. Y., Ghosh, A. K., Tozser, J., Louis, J. M., Harrison, R. W. and Weber, I. T. (2012). Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitors. *Protein Science*, 21, 339-350.

Tiwari, V., Ali, P. and Meshram, J. (2010). Microwave assisted synthesis of 3-(2-chloroquinolin-3-yl)-1-substituted phenyl prop-2-en-1-ones using K_2CO_3 as a mild, cheap and inexpensive catalyst. *International Journal of ChemTech Research*, 2, 1031-1035.

Toda, F. (1995). Solid state organic chemistry: Efficient reactions, remarkable yields, and stereoselectivity. *Accounts of Chemical Research*, 28, 480-486.

Tomar, V., Bhattacharjee, G. and Kumar, A. (2007). Synthesis and antimicrobial evaluation of new chalcones containing piperazine or 2, 5-dichlorothiophene moiety. *Bioorganic and Medicinal Chemistry Letters*, 17, 5321-5324.

Torres, H. A., Hachem, R. Y., Chemaly, R. F., Kontoyiannis, D. P. and Raad, I. I. (2005). Posaconazole: A broad-spectrum triazole antifungal. *The Lancet Infectious Diseases*, 5, 775-785.

Tsoleridis, C. A., Pozarentzi, M., Mitkidou, S. and Stephanidou-Stephanatou, J. (2008). An experimental and theoretical study on the regioselectivity of successive bromination sites of 7,8-dimethyl-2,4-diphenyl-3H-1,5-

benzodiazepine. Efficient microwave assisted solventless synthesis of 4-phenyl-3*H*-1, 5-benzodiazepines. *Arkivoc*, 15, 193-209.

Tuha, A., Bekhit, A. A. and Seid, Y. (2014). Synthesis and biological screening of some thienyl and phenyl pyrazoline derivatives as antimalarial agent. *Thai Journal of Pharmaceutical Sciences*, 38, 121-129.

Turan-Zitouni, G., Özdemir, A. and Güven, K. (2005). Synthesis of some 1-[(*N*, *N*-disubstituted thiocar bamoylthio) acetyl]-3-(2-thienyl)-5-aryl-2-pyrazoline derivatives and investigation of their antibacterial and antifungal activities. *Archiv der Pharmazie Chemistry in Life Science*, 338, 96-104.

Unsel, E. and Klotz, U. (1989). Benzodiazepines: Are they of natural origin? *Pharmaceutical Research*, 6, 1-3.

Unsel, E., Krishna, D. R., Fischer, C. and Klotz, U. (1989). Detection of desmethyldiazepam and diazepam in brain of different species and plants. *Biochemical Pharmacology*, 38, 2473-2478.

Usta, A., Yaşar, A., Yılmaz, N., Güleç, C., Yaylı, N., Karaoğlu, Ş. A. and Yaylı, N. (2007). Synthesis, configuration, and antimicrobial properties of novel substituted and cyclized '2', 3 "-thiazachalcones'. *Helvetica Chimica Acta*, 90, 1482-1490.

Van Heuverswyn, F., Li, Y., Neel, C., Bailes, E., Keele, B. F., Liu, W., Loul, S., Butel, C., Liegeois, F. and Bienvenue, Y. (2006). Human immunodeficiency viruses: SIV infection in wild gorillas. *Nature*, 444, 164.

Van Heuverswyn, F. and Peeters, M. (2007). The origins of HIV and implications for the global epidemic. *Current Infectious Disease Reports*, 9, 338-346.

- Vanangamudi, G., Subramanian, M. and Thirunarayanan, G. (2017). Synthesis, spectral linearity, antimicrobial, antioxidant and insect antifeedant activities of some 2, 5-dimethyl-3-thienyl chalcones. *Arabian Journal of Chemistry*, 10, S1254-S1266.
- Varala, R., Enugala, R., Nuvula, S. and Adapa, S. R. (2006). Ceric ammonium nitrate (CAN) promoted efficient synthesis of 1,5-benzodiazepine derivatives. *Synlett*, 7, 1009-1014.
- Varma, R. S., Kabalka, G. W., Evans, L. T. and Pagni, R. M. (1985). Aldol condensations on basic alumina: The facile syntheses of chalcones and enones in a solvent-free medium. *Synthetic Communications*, 15, 279-284.
- Vijaychand, S., Pavithra, G., Raghavendra, K. and Kumar, K. A. (2015). An efficient route to synthesis of pyrazoline carboxamides bearing thiophene moiety as antimicrobial agents. *Der Pharma Chemica*, 7, 85-89.
- Vogel, S., Barbic, M., Juergenliemk, G. and Heilmann, J. (2010). Synthesis, cytotoxicity, anti-oxidative and anti-inflammatory activity of chalcones and influence of a-ring modifications on the pharmacological effect. *European Journal of Medicinal Chemistry*, 45, 2206-2213.
- Wang, J., Hug, D., Gautschi, K. and Wieser, H. G. (1993). Clobazam for treatment of epilepsy. *Journal of Epilepsy*, 6, 180-184.
- Wei, W., Qunrong, W., Liqin, D., Aiqing, Z. and Duoyuan, W. (2005). Synthesis of dinitrochalcones by using ultrasonic irradiation in the presence of potassium carbonate. *Ultrasonics Sonochemistry*, 12, 411-414.
- Wen, P., Tie, W., Wang, L., Lee, M.-H. and Li, X.-D. (2009). Ultrasonic synthesis of 4,4'-dihydroxychalcone and its photochemical properties. *Materials Chemistry and Physics*, 117, 1-3.

- Whiting, P. J. (2003). GABA-A receptor subtypes in the brain: A paradigm for CNS drug discovery. *Drug Discovery Today*, 8, 445-450.
- Wick, J. (2013). The history of benzodiazepines. *The Consultant Pharmacist*, 28, 538-548.
- Wildmann, J. (1988). Increase of natural benzodiazepines in wheat and potato during germination. *Biochemical and Biophysical Research Communications*, 157, 1436-1443.
- Wildmann, J., Möhler, H., Vetter, W., Ranalder, U., Schmidt, K. and Maurer, R. (1987). Diazepam and *N*-desmethyldiazepam are found in rat brain and adrenal and may be of plant origin. *Journal of Neural Transmission*, 70, 383-398.
- Wildmann, J. and Ranalder, U. (1988). Presence of lorazepam in the blood plasma of drug free rats. *Life sciences*, 43, 1257-1260.
- Wildmann, J., Vetter, W., Ranalder, U. B., Schmidt, K., Maurer, R. and Möhler, H. (1988). Occurrence of pharmacologically active benzodiazepines in trace amounts in wheat and potato. *Biochemical Pharmacology*, 37, 3549-3559.
- Won, S.-J., Liu, C.-T., Tsao, L.-T., Weng, J.-R., Ko, H.-H., Wang, J.-P. and Lin, C.-N. (2005). Synthetic chalcones as potential anti-inflammatory and cancer chemopreventive agents. *European Journal of Medicinal Chemistry*, 40, 103-112.
- Wu, J.-H., Wang, X.-H., Yi, Y.-H. and Lee, K.-H. (2003). Anti-AIDS agents 54. a potent anti-HIV chalcone and flavonoids from *Genus Desmos*. *Bioorganic and Medicinal Chemistry Letters*, 13, 1813-1815.

- Wu, X., Wilairat, P. and Go, M.-L. (2002). Antimalarial activity of ferrocenyl chalcones. *Bioorganic and Medicinal Chemistry Letters*, 12, 2299-2302.
- Yang, Y., Zhang, T., Xiao, L., Yang, L. and Chen, R. (2010). Two new chalcones from leaves of *Morus alba L.* *Fitoterapia*, 81, 614-616.
- Yarchoan, R. and Mitsuya, H. (2013). Development of the first AIDS drugs: AZT and other dideoxynucleosides. In: LeGrice, S. and Gotte, M. (eds.) *Human immunodeficiency virus reverse transcriptase*. (1st ed.), (pp. 1-20). New York: Springer.
- Youssofi, M. H., Sahu, P. K., Sahu, P. K., Agarwal, D. D., Ahmad, M., Messali, M., Lahsani, S. and Hadda, T. B. (2015). Pom analyses of antimicrobial activity of 4*H*-pyrimido [2,1-*b*] benzothiazole, pyrazole, and benzylidene derivatives of curcumin. *Medicinal Chemistry Research*, 24, 2381-2392.
- Yusuf, M. and Jain, P. (2012). Synthesis, characterization and antimicrobial studies of new bispyrazolines linked via 3-aryl ring with aliphatic chains. *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy*, 96, 295-304.
- Yusuf, M. and Jain, P. (2014). Synthesis and antimicrobial studies of new bis [4, 5-dihydro-1-phenyl-5-thienyl-3-(phenyl-4-alkoxy)-1*H*-pyrazole] derivatives. *Journal of Heterocyclic Chemistry*, 51, 1162-1170.
- Zangade, S., Mokle, S., Vibhute, A. and Vibhute, Y. (2011). An efficient and operationally simple synthesis of some new chalcones by using grinding technique. *Chemical Sciences Journal*, 13, 1-6.
- Zangade, S. B., Mokle, S. S., Shinde, A. T. and Vibhute, Y. B. (2013). An atom efficient, green synthesis of 2-pyrazoline derivatives under solvent-free conditions using grinding technique. *Green Chemistry Letters and Reviews*, 6, 123-127.

- Zayane, M., Romdhane, A., Daami-Remadi, M. and Jannet, H. B. (2015). Access to new antimicrobial 4-methylumbelliferone derivatives. *Journal of Chemical Sciences*, 127, 1619-1626.
- Zervos, M., Silverman, J. and Meunier, F. (1994). Fluconazole in fungal infection: A review. *Infectious Diseases in Clinical Practice*, 3, 94-101.
- Zhang, C. Y., Liu, X. H., Wang, B. L., Wang, S. H. and Li, Z. M. (2010). Synthesis and antifungal activities of new pyrazole derivatives via 1,3-dipolar cycloaddition reaction. *Chemical Biology and Drug Design*, 75, 489-493.
- Zheng, Y., Ben, K. and Jin, S. (1999). Alpha-momorcharin inhibits HIV-1 replication in acutely but not chronically infected T-lymphocytes. *Acta Pharmacologica Sinica*, 20, 239-243.
- Zhong, W., Zhang, Y. and Chen, X. (2001). Simultaneous reduction of the nitro group and the azide group in o-nitrophenylazide induced by the $TiCl_4/Sm$ system: A novel synthesis of 2,3-dihydro-1H-1,5-benzodiazepines. *Tetrahedron Letters*, 42, 73-75.
- Zhou, X., Zhang, M. Y., Gao, S. T., Ma, J. J., Wang, C. and Liu, C. (2009). An efficient synthesis of 1, 5-benzodiazepine derivatives catalyzed by boric acid. *Chinese Chemical Letters*, 20, 905-908.